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Abstract 
Copy number variation has been linked to the development of various diseases, 
however copy number variants have not been investigated for associations with athletic 
performance. The present study investigated copy number variation of the Myosin Light 
Chain Kinase (MYLK)1 and MYLK-Antisense 1 (MYLK-AS1) genes for associations with 
athletic performance in a cohort of Lithuanian athletes and controls. We hypothesised that 
increased MYLK1 copy number and decreased MYLK-AS1 copy number would be 
associated with strength and power athletes (STP) and measures of muscle performance. 
DNA was extracted from blood samples of 407 athletes and controls. Copy number of the 
target genes was determined using a multiplexed quantitative-polymerase chain reaction and 
the use of a multicopy reference assay. A higher MYLK1 copy number was overrepresented 
in the STP compared with controls (p=0.028[OR=9.97, 95% CI: 1.19-83.81); however 
endurance athletes did not differ from controls or STP (p≥0.661; χ²≤0.829). Positive 
correlations between MYLK1 copy number and strength and power performance were 
detected. Individuals with three copies were able to produce more power in isokinetic tests, 
jump higher and sprint faster than individuals with two copies in the whole cohort and these 
correlations were stronger in the STP. The strongest correlations found were with MYLK 
copy number and isokinetic flexion of the arm in STP (p=0.003, R²=7.78).  MYLK-AS1 did 
not associate with athlete status or measures of athletic performance (p>0.05). The 
improvements in performance with increased copy number indicate that copy number 
variants are associated with improved skeletal muscle phenotypes. These results, further 
current knowledge of how genetic variants underpin muscle phenotypes and indicate that 
MYLK1 potentially could be used as a target for improvements in athletic performance and 
treatment of muscle wasting disorders. 
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Abbreviations 
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Chapter 1 - Introduction  
1.1 Background 
Skeletal muscle is the largest organ in the human body making up approximately 30% 
of body mass (Kostek et al., 2010; Pescatello et al., 2013). The amount of force that can be 
generated (i.e. muscle strength), is the primary measure of skeletal muscle function and is 
often used as an indicator of health. The functional capacity of skeletal muscle is of critical 
importance because the maintenance of strength is essential in the prevention and treatment 
of muscle wasting diseases, such as sarcopenia (Roth et al., 2000; Roubenoff, 2000) and 
metabolic disorders, such as type II Diabetes (Boulé et al., 2001). Skeletal muscle underpins 
other processes such as locomotion and movement (Kostek et al., 2010). Since skeletal 
muscle is critically important for force production and movement, it is clear that the quality 
of muscle is a regulator of both sporting performance and health. The age related decline in 
both muscle mass and strength has been termed sarcopenia (Roth et al., 2000; Roubenoff, 
2000; Metter et al., 2002; Goodpaster et al., 2006; Mitchell et al., 2012). Studies have shown 
the steady loss of skeletal muscle begins at 40-50 years of age and the rate of loss is of such a 
degree that by the age of 80 the typical loss of skeletal muscle fibres from the limbs is 50% 
(Faulkner et al., 2007; Mitchell et al., 2012). Despite the maintenance of a high level of 
physical fitness, the performance of ‘master’ athletes typically declines after the age of 40 
and by the age of 80 can be reduced by up to 65% (Faulkner et al., 2007). However, ‘master’ 
athletes are stronger than master non-athletes of the same age (Hawkins et al., 2003). Muscle 
strength is lost at a greater rate than muscle mass(Faulkner et al., 2007; Mitchell et al., 2012). 
Despite a strong correlation between muscle mass and strength, in older individuals gains in 
lean mass can occur with decrements in muscle strength, indicating that the quality of the 
muscle is the important factor (Goodpaster et al., 2006; Mitchell et al., 2012). Sarcopenia is 
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an important process to understand because it can lead to disability, falls and the loss of 
independence in otherwise healthy elderly individuals (Roubenoff, 2000; Metter et al., 2002; 
Goodpaster et al., 2006; Mitchell et al., 2012). It has been shown that individuals with higher 
muscle strength, in large muscle groups, have a greater survival rate from a range of diseases 
compared to individuals with lower muscle strength (Metter et al., 2002; Goodpaster et al., 
2006; Ruiz et al., 2009). Thus, understanding the determinants of muscle strength is an 
important area of scientific research from both a health and performance perspective.  
 
Muscle strength is a highly variable trait and at the two opposing ends of the muscle 
strength scale there are elite athletes and individuals who suffer from muscle wasting 
diseases. Various factors determine muscle strength including environmental factors, such as 
nutrition, level of physical activity (Tiainen et al., 2009), and behavioural factors, such as 
motivation to train and level of pain tolerance (Sallis et al., 1992; Boutelle et al., 2004). 
Physiological factors also have been shown to influence strength through a myriad of 
different ways such as fibre composition, cross sectional area and size of the muscles (Kostek 
et al., 2010). There is a significant genetic component to these behavioural and physiological 
factors. The interaction between the environment and the genetics of an individual are just as 
important in phenotype determination as either factor alone (Tiainen et al., 2009). Individuals 
who possess advantageous genetics and control their environment correctly have the greatest 
chance of developing into elite athletes. Therefore, muscle strength is a biological process 
which is determined which is partially determined by an individual’s genetics and supported 
by both the environment and the interaction between the genetics and the environment 
(Kostek et al., 2010). 
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The human haploid genome is encoded on deoxyribonucleic acid (DNA) sequences 
which consist of approximately 3 billion nucleotides (Kruglyak & Nickerson, 2001). DNA 
encodes 20,687 protein coding genes in all individuals (Bernstein et al., 2012). The sequence 
of any two human genomes are highly similar with estimates of over 99% identical, which 
leaves 3 million potential nucleotides that determine the large phenotypic differences both 
within and across different populations (Kruglyak & Nickerson, 2001). The variation in the 
sequence of DNA causes the genetic differences in phenotypes. If a genomic variant is found 
at greater than 1% within a population then it is termed a common variant, whereas if the 
variant is found at less than 1% then it is known as a rare variant. Typically rare variants have 
a large impact on the function of a gene and are consequently less tolerable; therefore 
reducing the likelihood of them being passed on to future generations. Common variants tend 
to be more tolerable and have small to no effect on a gene, thus giving them a higher chance 
to be passed on to future generations than mutations (Pollex & Hegele, 2007). 
 
Less than 2% of the human genome encodes for protein coding genes (Bernstein et 
al., 2012), and at least 5% of the genome has been shown to be under selection. Therefore it 
was thought regions other than protein coding regions were functional (Pheasant & Mattick, 
2007). The remaining 95% of the genome was referred to as ‘junk’ DNA because it had no 
obvious functional role. The completion of ENCODE project discovered that the majority of 
the ‘junk’ DNA has some form of biochemical function. A total of 80% of the genome has 
been shown to have some form of functional role on either RNA or chromatin (Bernstein et 
al., 2012). Most of this percentage acts post transcriptionally to modify coding RNAs to alter 
regulation or expression of coding RNA (Palazzo & Gregory, 2014). One such type of non-
coding gene which acts to control the level of mRNA is an antisense gene. Antisense 
transcripts have been shown to regulate the expression of sense transcripts through RNA-
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RNA interactions. These interactions can cause gene silencing through chromatin 
modifications, such as DNA methylation and histone modification or interference where the 
sense and antisense transcripts hybridize and are subsequently destroyed (Werner, 2013). 
 
1.2 Heritability of traits 
Heritability is defined as the proportion of the variability of a phenotype which is 
explained by genetic factors within a population (Visscher et al., 2008). Twin and family 
studies are the two main study designs used to detect the heritable component of traits 
associated with athletic performance (Beunen & Thomis, 2006). Family studies examine the 
similarity between siblings and their parents to estimate the variation in the genetic 
component. These studies typically overestimate the genetic component due to conflation 
with shared environment. Twin studies examine monozygotic (MZ) and dizygotic (DZ) twins 
to determine the genetic and environmental impact of a trait. MZ twins have nearly identical 
genomes and DZ twins only share ~50% of their genetic material (Shih et al., 2004). If the 
phenotypes of MZ twins are more similar then it is said there is a genetic component, 
whereas if the phenotype of DZ twins is equally similar then it is said there is a purely 
environmental impact on the heritability of the trait.  
 
Twin and family studies only show the heritability of a trait within the specific 
population which is being examined because factors such as race, sex and age can all affect 
the heritability differently depending on the population (Visscher et al., 2008). When the 
heritability of height is examined, the population specific aspect of heritability is highlighted. 
In Caucasian populations heritability of height in males has been shown to range from 87-
93%, whereas in females the heritability is estimated to be 68-84% (Silventoinen et al., 
8 
 
2003). The heritability of height also has been examined in a range of different populations of 
African descent. In Nigerians the heritability of height is estimated at 62%, whereas in 
African Americans the heritability is estimated to be 87%, while in Jamaicans the heritability 
is 76% (Luke et al., 2001). The age of the individuals examined influences heritability. 
Typically the heritability of a trait will change over the course of a lifetime because of 
different environmental impacts at certain points in life. For example body mass at birth is 
dependent on the uterine environment, as an infant body mass is determined by the maternal 
milk production and as an adult there is no maternal component which influences body mass 
(Visscher et al., 2008). Twin and family studies indicate there are several aspects of athletic 
performance which have been shown to have large heritable aspects associated with them. 
 
The heritability of aerobic performance is one of the most studied athletic 
performance traits. The early studies on heritability generally over or under estimated the 
genetic component because of a lack of control for bias such as, age or gender (Bouchard et 
al., 1986). The HERITAGE study is one of the recent studies which controlled for several 
factors (age, sex and body mass) and predicted the heritability of V̇O2 max and the 
trainability of V̇O2 max was approximately 50% in sedentary individuals (Bouchard et al., 
1998, 1999). Several other traits of athletic performance have been studied including muscle 
fibre composition, anaerobic performance and muscle strength and power. More recent twin 
studies have estimated that the genetic element of an individual’s athletic performance is 31-
85% (De Moor et al., 2007). 
 
The heritability of muscle strength traits is not as clear because in the literature there 
are a wide range of heritability estimates. Twin and family studies have shown there is a large 
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heritable factor associated with muscle strength; however, inconsistencies in study design 
have led to wide estimates in the heritability estimates of muscle strength. Some studies show 
the upper heritability estimates to be 96% (Huygens et al., 2004b), whereas other studies 
predict heritability of strength to be as low as 14% (Beunen & Thomis, 2006). One reason for 
the lack of clarity in the hereditary estimates of muscle strength is that there are a lot of 
different measureable aspects of strength which are not consistent in the literature (Thomis et 
al., 1998). Elbow extension and flexion has been shown to produce a higher heritability 
estimate than knee extension and flexion (Huygens et al., 2004b, 2004a). Despite the wide 
range in heritability estimates of muscle strength there is a clear genetic component which 
explains the variance in the phenotype (Costa et al., 2012). Unfortunately heritability studies 
do not actually inform about the causal genetic variant (Pitsiladis et al., 2013). To allow the 
identification of the causal variant which underlie the heritability further studies, such as 
gene-association studies, must be conducted. 
 
1.3 Genetic variation 
The most commonly studied form of genetic variations studied are single nucleotide 
polymorphisms (SNPs). SNPs occur when one nucleotide is exchanged for another in the 
sequence of a gene. SNPs can occur in protein-coding exons, non-coding intronic regions of 
genes and intergenic regions (Barreiro et al., 2008). The majority of SNPs fall within the 
introns of genes and thus typically do not have an effect on the function of the gene and are 
typically viewed as silent. There are occasions when intronic SNPs affect the splicing or 
expression of a gene and these SNPs may have an effect on the function of a gene (Choi et 
al., 2008; Millar et al., 2010). When a SNP falls within an exon it can be further classified as 
either non-synonymous or synonymous. Synonymous SNPs do not cause a change in the 
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amino acid and typically are silent or cause differential splicing of the gene. Non-
synonymous SNPs lead to a change in amino acid and typically have the largest effects 
because they can either cause premature truncation of the protein or change the class of the 
amino acid potentially reducing the stability of the protein (Pollex & Hegele, 2007). For 
example, if a SNP causes a change from a hydrophobic amino acid to a hydrophilic amino 
acid, this can influence the stability of the protein depending on the cellular location (Strub et 
al., 2004). The phenotypic consequence of a SNP will ultimately depend on the function of 
the gene that is affected. For example, a SNP variation in a gene that is functionally involved 
in the muscle contraction process may affect performance phenotypes. 
 
The R577X polymorphism of the α-Actinin-3 (ACTN3) gene is one of the most 
studied and well documented which is associated with skeletal muscle phenotypes (for a 
detailed review see Berman & North, 2010). The X allele leads to a loss of function of 
ACTN3 that is associated with a reduced performance in power and sprint activities (Moran 
et al., 2007; Walsh et al., 2008). A study of elite athletes found a reduction of the X allele in 
sprint athletes and the complete absence of the X allele in Olympic athletes (Yang et al., 
2003). Several other SNPs have been associated with muscle size, strength and power 
phenotypes (for a detailed review see Ahmetov & Fedotovskaya (2012)). One of the key 
studies which has driven associations between genotypes and muscle phenotypes is the 
FAMuSS study (Thompson et al., 2004). The FAMuSS study recruited a total of 1300 
individuals and genotyped them for around 500 polymorphisms and found associations with 
several genetic loci and physical activity levels and muscle size, strength and body 
composition at baseline and in response to resistance training (Pescatello et al., 2013).  
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Although SNPs are the most commonly studied class of genetic variant, they are not 
the only genetic variants that have been associated with functional consequences on 
phenotypes. The total heritability estimates of muscle performance traits have not been 
accounted for by SNP variation. Therefore, other classes of genetic variation, such as 
structural variants, may explain some of the missing heritability of muscle performance traits. 
 
1.4 Structural Variants 
Structural variation occurs when insertions, duplications or deletions of genetic 
material occur. The nature of a structural variant (SV) means it can not only impact several 
bases of a gene, but also several genes. Structural variants of the human genome can take the 
form of small deletions or insertions which impact up to 50 base pairs, through to large 
structural variants which can affect whole chromosomes (Boonpeng & Yusoff, 2013). The 
initial studies to detect genomic variation examined large structural variants because these 
studies were performed before the polymerase chain reaction (PCR) was invented. Without 
the technology to amplify the desired sequence of a gene, investigators relied on using 
microscope karyotyping and southern blot technology, which are limited to identifying large 
variants which affect large segments or whole chromosomes (Pollex & Hegele, 2007). The 
invention of PCR allowed the easy amplification of target gene sequences to identify SNPs, 
therefore the majority of studies moved into examining SNPs.  
 
Several methods exist to identify SVs, each with associated advantages and 
disadvantages. These methods can be categorised into two main approaches, genome-wide 
scans for global identification of SVs and targeted scans of candidate genes. For genome-
wide identification of SVs, the development of array based technology led to array-
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Comparative Genomic Hybridization and SNP array based methods for detection of SVs. 
These array based methods use probes to compare the intensity of DNA samples to identify 
gains or losses of genetic material (Boonpeng & Yusoff, 2013). For the targeted scans 
approach, the traditional methods used are Southern blotting and fluorescence in situ 
hybridization (FISH) (Pollex & Hegele, 2007). Both southern blots and FISH are infrequently 
used because of the drawbacks associated with each of the methods. Southern blots require a 
high quantity of DNA and is a laborious process, while FISH is not suited to identifying a 
partial deletion of genes (Hoebeeck et al., 2007), because of resolution limitations (Boonpeng 
& Yusoff, 2013). The most common and simplest method for SV detection is to use 
quantitative PCR (qPCR) to compare the fluorescence of a target sequence compared to a 
reference assay (Boonpeng & Yusoff, 2013). One issue with qPCR based SV detection is the 
use of a single gene as the reference assay (e.g. RNASE P or TERT) because SVs could 
affect the assay which can lead to the incorrect determination of copy number of the target 
gene (Table 1).  
Table 1 - Problems that can develop through the use of a single gene for the relative quantification of 
structural variants.  
Reference Assay 
Copy Number 
Target Gene Copy 
Number 
Calculated Copy 
Number of Target 
Correct copy Number for 
Target Gene 
1 2 4 No 
2 2 2 Yes 
3 2 1.33 No 
 
1.5 Copy number variation 
Generally it is accepted that individuals have two copies of every gene, one inherited 
from their mother and one inherited from their father; however, it has been discovered that 
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the variation in copy number of a gene because of duplications and deletions of genetic 
material is widespread (Yang et al., 2013). Advances in genotyping and the human genome 
project allowed the investigation of gene copy numbers at a subchromosomal level (Lobo, 
2008). A SV of DNA of 1000 nucleotides or more which differs in copy number from a 
reference genome is classified as a copy number variant (CNV) (Redon et al., 2006). In 2004, 
the first papers to identify the widespread extent of CNVs throughout the human genome 
were published (Sebat et al., 2004; Iafrate et al., 2004). Both of these studies identified 
approximately 250 regions of copy number losses or gains in two different cohorts of 
unrelated individuals. A larger study of 270 individuals identified 1447 CNV regions 
throughout the human genome which affected 360 mega bases of DNA; equivalent to 12% of 
the total human genome and between 6-19% of any chromosome (Redon et al., 2006). A 
more recent study identified that on average 5% of the genome is affected by CNVs (Conrad 
et al., 2010). These CNVs can either be inherited from parents or rise from de novo 
mutations, where both parents have a normal copy number at the region of DNA in question. 
Studies have shown that monozygotic twins can differ in copy number for genes (Hastings et 
al., 2009) and the same individuals can have a different copy number depending on the tissue 
examined (Piotrowski et al., 2008).  
 
With the vast distribution of CNVs throughout the genome in a range of different 
organisms it is expected that they will contribute to the phenotypic differences between 
individuals. The main way CNVs will influence a phenotype will be through an alteration of 
gene dosage, causing a disturbance in coding sequences or disturbing the long-range 
regulation of genes through alteration of chromatin environment (Stranger et al., 2009). 
Between 85-95% of CNVs examined have been associated with changes in the expression of 
the affected genes (Stranger et al., 2009; Henrichsen et al., 2009). Deviation in gene copy 
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number associates with changes in the amount of the final protein levels. The proteins which 
do not show altered product tend to be components of complexes (Tang & Amon, 2013). On 
dosage sensitive genes, which have no compensatory mechanism, the presence of a 
duplication or deletion will directly increase or decrease the expression of the gene, 
respectively (Pollex & Hegele, 2007). When gene duplications occur there are several 
consequences for gene expression depending on the inclusion or absence of regulatory 
elements. If complete duplication of a gene including the regulatory region occurs there will 
be a greater increase in expression than if partial duplication of a gene occurs.  Duplication of 
a gene can reduce expression level if the duplicated region ends up in different regulatory 
regions, such as near insulators or repressors, a reduction in expression will be observed. 
Duplications also can reduce expression if they prevents access to the regulatory machinery 
preventing efficient transcription (Henrichsen et al., 2009).  
 
The association of CNVs with changes in phenotypes is not a recent development. 
One of the earliest functional CNVs to be identified occurred 78 years ago when a 
duplication in the Bar gene in Drosophila was discovered to narrow the eye field (Bridges, 
1936). The change in copy number in any number of genes is not well tolerated and often 
leads to the development of disease (Hastings et al., 2009). Most studies examining CNVs in 
humans have examined the deleterious nature of CNV on phenotypes in diseased populations 
and have led to various associations between CNVs and disease phenotypes (Almal & Padh, 
2012). Various neurological disorders including Parkinson’s disease (Singleton et al., 2003; 
Pankratz et al., 2011), Alzheimer’s disease (Sleegers et al., 2006) and Autism (Weiss et al., 
2008) have been associated with CNVs. Numerous forms of cancers, such as prostate, breast 
and colorectal have also been associated with CNVs (Yang et al., 2013). Several chronic 
health related diseases have also been associated with CNVs including various cardiovascular 
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diseases (Pollex & Hegele, 2007) and metabolic disorders including both type I (Grayson et 
al., 2010) and type II (Jeon et al., 2010) Diabetes. There have been many CNVs found on 
known candidate genes for body mass. For example, the deletion of a 2.1Mb region which 
spans the UPC1 and IL15 genes increases the risk of obesity (Wang et al., 2010). CNV has 
previously been associated with lean body mass. Individuals with two copies of CNV2073 
had 6.9% greater lean body mass than individuals with 3 copies and 11.2% more than 
individuals with 4 copies. One gene which is located in the region of CNV2073 is Gremlin1 
which has already been reported as a candidate for lean body mass by linkage studies and 
molecular function studies (Hai et al., 2012). Gains of two CNVs (CNV1191 and CNV2580) 
have also associated with decrease in appendicular lean body mass (Ran et al., 2014).  
 
Despite most of the associations with CNVs being with diseased phenotypes, CNVs 
have been shown to occur with healthy populations and have advantageous consequences. 
Salivary amylase (AMY)1 is the most common example of a gene which has CNV with 
beneficial effects. In populations with high starch diets it has been shown that there is an 
increase in the AMY1 copy number and elevated expression of the salivary amylase protein 
which is responsible for starch hydrolysis (Perry et al., 2008). Increased copy number for 
AMY1 also has been associated with a significantly reduced BMI and risk of obesity (Falchi 
et al., 2014). CNVs of other genes have been associated with beneficial phenotypes such as 
delayed progression of spinal muscular atrophy with an increase in the number of copies of 
the survival motor neuron (SMN)2 gene (Elsheikh et al., 2009). Patients with three or four 
copies of SMN2 have been shown to produce higher force for grip, elbow flexion, and knee 
extension and flexion compared to the patients with two copies; none of the increases reached 
statistical significance (Febrer et al., 2010). These studies show that CNVs can consequences 
in clinical populations and in the general population. To date no studies have investigated the 
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impact of CNVs with muscle performance in athletes. We would predict that because of the 
previous associations with disease, that CNVs in genes related to athletic performance will 
have phenotypic consequences for muscle function. 
 
1.6 Myosin Light Chain Kinase 
The Myosin Light Chain Kinase (MYLK) genes encode for the MYLK proteins 
which are responsible for the phosphorylation of the regulatory light chain of myosin (RLC). 
Western blot analysis has shown that the different MYLK proteins differ in the site of 
expression (Zhi et al., 2005). MYLK1 has been shown to be expressed ubiquitously 
throughout all tissues, however the main site of expression of the kinase is in smooth muscle 
and therefore it has been termed the smooth muscle MYLK (smMLCK). MYLK2 has been 
shown to express the skeletal muscle MYLK (skMLCK) specifically in skeletal muscle and 
predominantly in the type II fast twitch fibres (Zhi et al., 2005; Herring et al., 2010; Kamm & 
Stull, 2011). MYLK3 encodes for the cardiac MYLK (cmMLCK) protein which is expressed 
mainly in the cardiac myocytes (Takashima, 2009). The phosphorylation of the RLC of 
myosin is important in the contraction process for all three of the muscle types (smooth, 
skeletal and cardiac) (Takashima, 2009). In general MYLK controls the phosphorylation of 
the RLC of myosin to allow interaction between myosin and actin filaments in the contraction 
of muscle fibres (Stull et al., 2011).  
 
Each of the MYLK proteins have different roles specific to the type of muscle it is 
associated with. In smooth muscle, an increase in intracellular calcium leads to the activation 
of smMLCK by calmodulin (Kamm & Stull, 2001). The phosphorylation of the RLC by 
smMLCK has been shown to be sufficient to initiate the contraction process in smooth 
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muscles through the activation of myosin ATPase (Figure 1)(Kamm & Stull, 2001; Murthy, 
2006). In both skeletal and cardiac muscle MYLK activation is not the key step in the 
initiation of the contraction process because it is not the calcium sensor, instead that role is 
played by troponin. The binding of calcium to troponin causes a conformational change, 
allowing  interaction between the myosin cross-bridges and actin filaments which leads to the 
development of force (Farah & Reinach, 1995). In smooth muscle, RLC phosphorylation by 
smMLCK affects the myosin ATPase activity, whereas in skeletal and cardiac muscle there is 
no impact on ATPase activity by the specific MLCK. In skeletal muscle, the phosphorylation 
of RLC by skMLCK leads to changes in properties of the myosin cross-bridges (Figure 
1)(Kamm & Stull, 2011). In mice with ablated MYLK2, it has been shown that there is a role 
for RLC phosphorylation in the potentiation of isometric twitch force. The knockout mouse 
displays a reduction in the phosphorylation of the RLC and produces significantly lower 
twitch force (Zhi et al., 2005; Gittings et al., 2011). There is also evidence of some RLC 
phosphorylation in the knockout mouse which suggests there could be some redundancy 
between skMLCK and smMLCK (Takashima, 2009). The functional role of MYLK1 and 
MYLK2 in the contraction of muscle and the suggestion of a potential functional redundancy 
for skMLCK by smMLCK makes both of these genes candidate genes for genetic variation 
which is functionally involved in muscle strength and power phenotypes. 
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Figure 1 - Role of MLCK in the contraction of skeletal and smooth muscle (adapted from Takashima 
(2009)). SR; sarcoplasmic reticulum, Ca
2+
; calcium ions, MLCK; myosin light chain kinase, sk; skeletal 
muscle, sm; smooth muscle, MLC; myosin regulatory light chain. 
 
 Previous SNP association studies attempted to examine if variation in MYLK2 is 
associated with muscle function. However, the SNPs selected in these studies are found to 
encode for MYLK1 (C49T (rs2700352) and C37885A (rs28497577)) (Clarkson et al., 2005; 
Deuster et al., 2013). Despite both of the studies attempting to examine variation in MYLK2 
but instead examining MYLK1, associations with strength phenotypes were found. The first 
study to examine SNP variation in MYLK1 and muscle phenotypes studied 157 patients who 
performed a muscle damage protocol of the elbow flexors to investigate the genetic 
determinants of exertional muscle damage (Clarkson et al., 2005). The two muscle strength 
phenotypes examined were baseline strength and greater strength loss following eccentric 
exercise of the elbow flexors. A key finding of the study was contrary to the hypothesis as 
they found patients homozygous for the T allele of C49T produced significantly higher 
baseline strength values. They also found that patients homozygous of the C allele of 
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C37885A showed significantly lower post exercise strength loss. A second study examined 
the risk of developing exertional rhabdomyolysis in 47 disease sufferers and 134 control 
individuals to identify polymorphisms associated with the disease (Deuster et al., 2013). Two 
of the polymorphisms that were investigated were the same MYLK1 SNPs as the Clarkson 
study. They did not find any association with C49T which is consistent with the previous 
study only finding a relationship with baseline strength. Individuals homozygous for the A 
allele of MYLK1 C37885A were determined to be 5 times more likely to suffer from 
exertional rhabdomyolysis than individuals who were CC homozygotes (Deuster et al., 
2013), which is consistent with the findings that the C allele causes lower strength loss 
following exercise (Clarkson et al., 2005). The results of the two studies show that MYLK1 
C49T and C37885A are both associated with muscle function changes in clinical populations 
(Clarkson et al., 2005; Deuster et al., 2013); however these SNPs have yet to be examined in 
an athletic cohort. 
 
Unpublished data from our laboratory examined the same SNPs of MYLK1 as 
previous studies (Clarkson et al., 2005; Deuster et al., 2013) in a cohort of athletes and 
control individuals in an attempt to find if the associations with muscle performance 
phenotypes in clinical populations remain when examined in an athletic population. Three 
SNPs of MYLK2 were also examined to test if variation in the skeletal muscle specific gene 
also associated with muscle performance phenotypes. No muscle strength phenotypes were 
associated with the SNPs of MYLK2; however, associations were made with isokinetic test 
performance and the MYLK1 SNPs. Given that SNP variation has been associated with 
functional changes in muscle performance, we hypothesise that CNVs will affect the function 
of MYLK1 and therefore be associated with muscle strength phenotypes.  
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The antisense gene of MYLK1, called MYLK-antisense 1 (MYLK-AS1) is 
potentially another candidate gene for functional variation associated with athletic 
performance. Antisense genes are thought to functionally act to regulate gene expression, 
however the specific role of these mRNA genes is not fully understood (Werner, 2013). 
These antisense transcripts form duplex RNA through hybridization with the sense transcript. 
These interactions can reduce the gene expression and decrease the levels of protein synthesis 
by preventing the translational machinery access to the sense transcript (Kumar & 
Carmichael, 1998). Another potential role of antisense genes is to control the splicing of the 
associated sense gene, by preventing access to splice sites (Morrissy et al., 2011). Some 
antisense genes have been shown to stabilise the expression of the sense genes through 
competition for microRNA binding sites and RNA motifs (Werner, 2013). Several antisense 
genes have been shown to be functional however the mechanisms underlying the function 
have yet to be identified.  It is thought that MYLK-AS1 may act to reduce the expression of 
MYLK1 leading to a reduction in RLC phosphorylation and decreased muscle performance.  
The Database of Genomic Variants (MacDonald et al., 2014) identified the presence 
of CNVs which span the whole of the MYLK1 and MYLK-AS1 genes. There have been no 
CNVs detected which span the whole of the MYLK2 gene. The studies which identified the 
presence of CNVs on MYLK1 and MYLK-AS1 did not include any functional measures 
therefore the phenotypic consequences of changes in copy number in these genes is unknown 
(Wong et al., 2007; Itsara et al., 2009). 
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1.7 Aims & Objectives 
The aim of the present study was to assess copy number variation in a cohort of 
athletes and control individuals for the first time and examine if it is associated with strength. 
MYLK1 and MYLK-AS1 have been selected as the target genes to examine if some of the 
missing heritability of muscle strength and power traits can be explained by CNVs in genes 
previously associated with functional SNP variation. There are three main objectives of the 
project: (1) to examine the extent of variation in MYLK1 and MYLK-AS1 copy number in 
athletes and control; (2) to examine if there is a different relationship between MYLK1 and 
MYLK-AS1 copy number between different groups of athletes (endurance and 
strength/power athletes) and controls; (3) to investigate how the copy number of the two 
target genes associates with quantitative phenotypes associated with strength and power. We 
hypothesise that increases in MYLK1 copy number will be overrepresented in the strength 
athletes and consequently also be associated with increased performance in tests of strength 
and power phenotypes. We expect to find the opposite in MYLK-AS1 with an 
underrepresentation in the strength athletes and decreased performance in measures of 
strength and power. The result of this study will further the understanding of genetic variation 
which influences muscle function. 
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Chapter 2 - Materials and Methods 
2.1 Ethical Approval 
 Ethical approval was obtained for the genetics of Lithuanian athletes (GELA) study 
by the Lithuanian State Bioethics Committee and the University of Stirling, School of Sport 
Research Ethics Committee. The study abides by the principles outlined in the Declaration of 
Helsinki. Informed consent in writing was obtained from each participant prior to 
participation in the study. 
 
2.2 Participant characteristics 
 The present study utilised the pre-established GELA cohort which consists of native 
Lithuanians (n=447) from the Lithuanian Sports University (Kaunas, Lithuania). All 
participants were males (17-37 years old) and where related individuals were recruited only 
the individual who competed at the highest level was retained for analysis. All participants 
underwent phenotype determination for a range of standard physiological tests (see: 
phenotype data). To confirm all participants were performing close to their peak at the time 
of phenotype determination, any participants unable to perform the physiological tests due to 
injury or disease were excluded from the study. Any athletes who could not be categorised as 
strength-power (STP), endurance (END) or they no longer performed at their top level were 
also excluded from the study. A total of 407 participants remained for further analysis 
following the exclusions of the participants who did not meet the necessary criteria (n=40). 
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 The participants were divided into 3 separate groups: control individuals (n=197), 
strength and power athletes (STP; n=126) and endurance athletes (END; n=84). Descriptive 
characteristics of all participants can be found in Table 2. All athletes trained a minimum of 
twice a week, whereas the control participants did not take part in organised physical activity 
more than twice a week and did not compete in competitive sports unless it was a low impact 
sport. STP included weightlifters, combat athletes, field athletes (discus, javelin and long 
jump) gymnasts, team sport individuals (handball, volleyball, basketball and football), short 
distance swimmers and runners, a motocross-rally driver and a high-diver. END included 
long-distance runners, cyclists, triathletes, a rower, modern pentathletes, orienteers, skiers 
and walkers. Each of the athlete subgroups was further divided by highest level of 
competition. International athletes (n=14) were the participants who represented Lithuania at 
the Olympic Games or World Championships. National athletes (n=97) were ranked in the 
top 3 for their sport or have been included in a Lithuanian national sport squad but did not 
compete internationally. Regional athletes (n=63) were defined as athletes that were members 
of their local area squad. Other athletes (n=36) were a mixture of athletes who did not 
achieve any of the above levels or chose not to compete but trained regularly. The number of 
athletes who performed each sport and the level of performance of these athletes can be 
found in Appendix A. 
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Table 2 - Descriptive characteristics of the groups of participants. Values are means ± 95% CI. FFM; fat 
free mass, STP; strength and power athletes, END; endurance athletes 
Phenotype 
Control Athletes STP END 
(n=197) (n=210) (n=126) (n=84) 
Age (yrs) 23.98 ± 0.60 21.77 ± 0.46 21.83 ± 0.57 21.68 ± 0.78 
Height (cm) 180.29 ± 0.83 181.65 ± 2.58 183.27 ± 4.23 179.27 ± 1.17 
Body mass (kg) 77.00 ± 1.50 76.90 ± 1.62 81.30 ± 2.26 70.35 ± 1.44 
Body Fat (%) 15.80 ± 0.73 12.99 ± 0.48 14.12 ± 0.65 11.29 ± 0.51 
FFM (kg) 64.28 ± 0.95 66.34 ± 1.63 69.07 ± 2.55 62.37 ± 1.20 
Training experience (yrs) N/A 8.04 ± 0.80 8.83 ± 1.05 6.87 ± 1.17 
Training volume (hr/wk) N/A 11.4 ± 1.13 10.72 ± 1.55 12.36 ± 1.6 
 
2.3Phenotype data 
Participants were required to attend the laboratory for testing on three separate 
occasions having rested for at least 12 hours and fasted for at least 2 hours. On entry to the 
laboratory on the first day all participants were assigned a unique ID code to allow all data to 
be stored in an anonymous manner. All participants had a 10 ml venous blood sample 
extracted into an EDTA container and frozen at -80 
o
C prior to DNA extraction. During the 
laboratory visits the participants were required to fill out a number of questionnaires and 
complete a range of standardised physiological tests, which were carried out by trained 
individuals. The laboratory visits allowed detailed phenotypes to be collected including 
measures of anthropometrics, body composition, endurance performance, strength 
performance and cardiac size and function. For the current analysis a subset of the 
phenotypes which are indicative of strength and power performance. The selected tests 
included measures of isolated muscle group force production such as hand grip strength and 
isokinetic dynamometry for extension and flexion of the right and left legs and arms at a 
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range of speeds (30-180 °/s) and performance in whole body movements such as number of 
pull-ups, countermovement jump and static jump height and time to complete a 30 metre 
sprint (Details on the tests performed in Appendix B). 
 
2.4 DNA Extraction 
All extractions were performed at the University of Stirling. Genomic DNA was 
extracted from 200 µl of whole blood using silica columns (Macherey-Nagel GmbH & Co. 
KG, Germany) and extraction buffers (Qiagen Ltd, UK) using the QIAamp Spin DNA 
extraction protocol. DNA yield and quality was checked by absorbance on a Synergy HT 
microplate reader (BioTek, USA) with Gen5.0 software. Samples with a yield of less than 10 
ng/µl were re-extracted (concentration of DNA samples can be found in Appendix C). All 
DNA samples were stored at -20 
o
C prior to analysis. 
 
2.5 Copy Number Assays  
To analyse the copy number of MYLK1 and MYLK-AS1, a multiplexed quantitative 
real-time polymerase chain reaction (qPCR) method was used. Primer and hydrolysis probe 
assays (Integrated DNA Technologies Inc, USA) were designed to amplify a region which 
lies in the introns of the genes of interest. Care was taken to ensure that no SNPs had been 
reported previously in European populations within the primer and probe sequences. The 
Basic Local Alignment Search Tool (BLAST, National Centre for Biotechnology 
Information) was used to ensure that the primers and probes were specific to the genes of 
interest and did not recognise any other sequences. The MYLK1 assay contains the forward 
primer (5’-ACATACACAAGGTCAGTCACG-3’), reverse primer (5’- 
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GAGTCTGAACTCACAACGGTAG -3’) and Cy5 labelled probe (5’-
CAAGCCACTGATGAAGTGATGGCA-3’) which amplifies a 99 base pair region. The 
MYLK-AS1 assay contains the forward primer (5’-TCCAGAGAGAGAGAAACCTTAGTT-
3’), reverse primer (5’- GAGATGGTCCAGGATAGTAAAGATAAAG-3’) and 6-FAM 
labelled probe (5’-TGTCCAGGAAGGGAGGAAGAAGAGT-3’) which amplifies a 101 
base pair region. Figure 2 displays the location of these two amplicons. For determination of 
gene copy numbers the Type-it CNV probe PCR kit + qC kit was used including the 
multicopy Type-it CNV Reference Probe Assay Solution (Qiagen Ltd, UK) of a known copy 
number labelled with a MAX fluorescence probe. The use of this reference assay was 
selected as the control assay because it has a copy number of 36 which makes it more robust 
to CNVs than traditional assays which use single copy genes (Table1). The fluorescence 
emission spectra of the 6-FAM (494-518), MAX (524-557) and Cy5 (643-667) dyes are all 
close together, therefore, colour compensation was performed to optimise fluorescence 
detection to prevent any crossover fluorescence from the other probes being picked up. 
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Figure 2 – Location of the MYLK1 and MYLK-AS1 sequences on Chromosome 3 according to the 
Genome Reference Consortium Human Build 38. Bp; base pair location on chromosome 3, MYLK1; 
myosin light chain kinase1, MYLK-AS1; myosin light chain kinase-antisense1. 
 
All samples were run in triplicate and each plate contained a non-template control 
also run in triplicate. A reaction volume of 12.5 µl was used for all reactions, containing 6.25 
µl of 2x Type-it CNV Probe PCR Master Mix (Qiagen Ltd, UK), 0.5 µl of 25x Ref assay, 0.5 
µl of 25x MYLK1 assay, 0.5 µl of 25x MYLK-AS1 assay, 2.75 µl of nuclease-free water and 
2 µl of DNA normalised to 5 ng/µl. All reactions were performed on the same LightCycler 
480 (Roche Diagnostics Ltd, UK) system and included activation at 95 
o
C for 5 min followed 
by 40 cycles of alternative 30 s periods at 95 
o
C and 60 
o
C as recommended by the Type-it 
CNV probe protocol.  
 
2.6 Copy number determination 
 The median absolute deviation method was used to identify any outlier crossing point 
(Cp) within each triplicate for each assay. The mean of the remaining Cps in each triplicate 
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was calculated to give the corrected Cp for each sample in the cohort. The median absolute 
deviation was also used to identify any samples from the cohort which needed to be repeated 
because of outlying corrected values. The difference between the Cp of genes of interest and 
the reference assay was calculated to allow determination of the copy number for each 
participant. 
 
In qPCR reactions, primers which amplify at an efficiency of 90-110% are acknowledged as 
acceptable for the amplification of targets (D’haene et al., 2010). There are a number of 
statistical methods which can be used to determine qPCR efficiency all of which can produce 
a different result because of the different algorithms used (Ruijter et al., 2013). Small 
changes in reaction efficiency can dramatically alter copy number estimates (Yuan et al., 
2007). Standard curves of serial dilutions and LinRegPCR (Ramakers et al., 2003) were used 
to calculate the efficiencies of the MYLK1 and MYLK-AS1 assays. Different values (range 
85-107%) were obtained for both of these measures which would change the number of 
copies of these genes. The normal copy number for most genes is two and in previous studies 
only four out of ~1700 individuals have been detected with alterations (duplications or 
deletions) of copy number (Wong et al., 2007; Itsara et al., 2009). In the present cohort, we 
calculated that efficiencies of 105.7% and 99.8% for MYLK1 and MYLK-AS1 respectively 
would lead to a median copy number of two. These efficiencies are within the range that we 
calculated; therefore we scaled the obtained Cp values using these efficiencies. It should be 
noted that the scaling of these data will not affect the associations with quantitative 
phenotypes. All statistical analyses were performed with, and without, the scaling of data and 
similar results were obtained. To generate the copy number for each participant, copy number 
was grouped into the nearest integer as has been previously described (Gonzalez et al., 2005; 
Cantsilieris et al., 2012). The grouping of copy number may reduce the power to detect 
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associations, however it leads to clearer interpretation of associations and similar results were 
obtained when correlations were performed on the raw copy number or integer copy number.  
 
2.7 Statistical Analysis 
 All statistical analysis was carried out using Minitab (version 16, Minitab, State 
College, PA). All phenotype data were tested for normality using the Ryan-Joiner test (Ryan, 
1974). Any data that were not normal were transformed using the Box-Cox transformation to 
give better approximation of the normal distribution. Data were back-transformed for display 
in figures and tables, thus all values are means ± 95% confidence intervals unless otherwise 
stated. 
 
2.7.1 Comparison of copy number / genotype between groups 
 Chi-squared contingency tables (corrected using the Yates correction for continuity 
(Yates, 1934) where appropriate) were used to determine if the athletic groups differed from 
each other or from the control group in copy number for each of the target genes. Differences 
between the groups were examined using odds ratios (OR) to identify the likelihood of an 
individual being assigned to a particular athlete group or performance level achieved based 
on copy number. The significance of the OR was determined using chi squared contingency 
tables and 95% confidence intervals (CI). Significance was accepted as chi-squared p<0.05. 
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2.7.2Association of copy number with physiological variables 
 All phenotype data were z-scored using the overall mean and standard deviation. 
Phenotype data were separately z-scored within each of the subgroups to account for group 
differences. Pearson’s correlation analysis was performed using the z-scored phenotype data 
with and without group corrections to identify associations between copy number and 
physiological variables. The Benjamini-Hochberg (BH) correction for multiple testing was 
applied to control for false discovery rate separately for isolated muscle and whole body 
performance tests (Benjamini & Hochberg, 1995). Pearson’s correlations were accepted as 
significant where p-value < α-value determined in BH correction. For the significant 
correlations, two tailed T-tests were used to compare the means in quantitative phenotypes 
for each copy number. T-test significance was accepted as p<0.05.  
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Chapter 3 - Results 
3.1 Copy number detection in each group 
Copy number determination was achieved for 405 of the individuals (99.5% success). 
The same two individuals failed for both target genes and the reference assay. Out of the 405 
individuals examined, 12 (3%) individuals have variations of MYLK1 away from the normal 
copy number of two, whereas 18 (4.5%) individuals have variations of copy number for 
MYLK1-AS1. Only one control had a deviation of copy number for MYLK1 which is at the 
frequency expected (Wong et al., 2007; Itsara et al., 2009); however, controls with deviations 
in copy number for MYLK-AS1 are found at a greater frequency than anticipated. It should 
be noted, however, that previous studies used to determine expected frequencies used a range 
of ethnicities which could differ in allele frequencies (Wong et al., 2007; Itsara et al., 2009). 
In the group of athletes (N=208), 11 and 12 have alterations away from the normal copy 
number of two for MYLK1 and MYLK-AS1 respectively. Deviations away from a copy 
number of two have been shown to be a more regular occurrence in STP than END for both 
of the target genes. The number of deletions and duplications within each of the groups can 
be found in Table 3. 
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Table 3 – The copy number of the individuals within each of the groups. Values are the total number with 
the percentage of the group in brackets. CN; copy number, STP; strength and power athlete, END; 
endurance athlete 
 
MYLK1 CN (%) MYLK-AS1 CN (%) 
 
1 2 3 1 2 3 
Total 
(n=405) 
3 (0.74) 393 (97.04) 9 (2.22) 3 (0.74) 387 (95.56) 15 (3.70) 
Athlete 
(n=208) 
3 (1.44) 197 (94.71) 8 (3.85) 2 (0.96) 196 (94.23) 7 (3.41) 
STP 
(n=124) 
2 (1.61) 116 (93.55) 6 (4.84) 1 (0.81) 118 (95.16) 5 (4.03) 
END (n=84) 1 (1.19) 81 (96.43) 2 (2.38) 1 (1.19) 81 (96.43) 2 (2.38) 
Control 
(n=197) 
0 (0.00) 196 (99.49) 1 (0.51) 1 (0.51) 188 (95.43) 8 (4.06) 
 
3.2 Copy number differences between groups 
A trend exists where the copy number of MYLK1 in the athletes differs to the 
controls (χ² =5.150, p=0.076). When athlete subgroups are examined, the distribution of copy 
numbers is significantly different between STP and the controls (χ² =6.103, p=0.047). END 
did not differ from the controls (χ² = 0.828, p=0.661) or STP (χ² =0.436, p=0.804) for 
MYLK1 copy numbers. OR display that athletes are less likely to have two copies (p=0.005) 
of MYLK1 and there is a trend where athletes are more likely to have three copies (p=0.051) 
compared to the controls. STP are less likely to have two copies (p=0.003) and more likely to 
have three copies (p=0.028) than controls (Table 4). There were no associations between 
MYLK-AS1 copy number and any of the groups (χ² = 0.114-0.268; p=0.874-0.945). 
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Table 4 - Odds Ratios for athlete group vs copy number for MYLK1. Odds Ratio of N/A is because none of the 
controls have a copy number of one for MYLK1. STP; strength and power athletes, CI; Confidence interval 
Comparison 
Copy 
number 
p-value 
Odds Ratio (95% 
CI) 
Athletes vs 
Controls 
1 0.264 N/A 
2 0.005 0.09 (0.01-0.71) 
3 0.051 7.84 (0.97-63.27) 
STP vs Controls 
1 0.287 N/A 
2 0.003 0.07 (0.01-0.60) 
3 0.028 9.97 (1.19-83.81) 
 
In the next stage of analysis, the highest level of competition was investigated for 
associations between copy numbers of the target genes. For MYLK1, the only association 
found with level of performance was between Regional level athletes and the controls (χ² 
=6.618; p=0.037). The Regional athletes are less likely to have two copies (p=0.003 [OR 
0.06; 95% CI:0.01-0.5]) and more likely to have three copies (p=0.013 [OR 13.75; 95% 
CI:1.51-125.52]) than the controls. No associations were found for highest level of 
competition and MYLK-AS1 copy number (χ² =0.055-1.644, p=0.440-0.973). 
 
3.3 Copy number associations with quantitative measurements 
 To account for the difference in training of the participants, the relationship between 
copy number and quantitative phenotypic measurements has been investigated with and 
without corrections for subgroup (Table 5 and 6). To test for associations which could 
potentially confound other analyses, correlations were made between MYLK1 / MYLK-AS1 
copy number and age, height, body mass, training history and volume. No significant 
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correlations existed between any of these variables and MYLK1 / MYLK-AS1 copy number 
before or after correction for subgroup (p=0.091-0.878).  
 
Copy number of the target genes was investigated for associations with selected 
phenotypes associated with strength and power performance for isolated muscle groups and 
whole body movements. To assess the correlation between these phenotypes and copy 
number, Pearson’s correlations were performed with BH correction for multiple testing was 
applied to reduce the risk of type 1 statistical errors. Overall in the whole cohort MYLK1 
copy number was associated with strength and power phenotypes, in isolated muscle groups 
and whole body movements (Table 5). The average variance explained by these significant 
correlations is 1.5% with the highest variance being explained by isokinetic extension of the 
elbow (2.76%). After correction for subgroup the associations for counter movement jump 
and sprint performance are lost whilst the remaining associations are weakened (Table 5). 
The average variance explained by the group corrected correlations is 1.35 %. The highest 
percentage of the variance is still found with the isokinetic extension of the elbow, however 
the variance drops down to 2.34 %. None of the strength and power phenotypes correlated 
with copy number for MYLK-AS1 with or without the correction for subgroup (Table 6).
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Table 5 - Pearson's correlation coefficient results for MYLK1 copy number and quantitative variables 
before and after correction for subgroup. Significant (p<0.05) values are highlighted in bold. Values 
marked by * have a p-value lower than the acceptable alpha value according to the BH correction. 
kgFFM; kilogram of fat free mass, IKR, isokinetic right; IKL, isokinetic left  
Trait 
MYLK1 
Before Subgroup Correction After Subgroup Correction 
p-value Coefficient 
R
2
 
(%) 
p-value Coefficient 
R
2
 
(%) 
Number of pull-ups 0.08 0.089 0.792 0.725 0.018 0.032 
Counter movement jump height (cm) 0.049 0.099 0.980 0.132 0.076 0.578 
Static jump height (cm) 0.009* 0.132 1.742 0.022* 0.116 1.346 
Sprint 0-10 (s/kgFFM) 0.022* -0.116 1.346 0.077 -0.09 0.810 
Sprint 10-20 (s/kgFFM) 0.018* -0.121 1.464 0.055 -0.097 0.941 
Sprint 20-30 (s/kgFFM) 0.028 -0.112 1.254 0.076 -0.09 0.810 
Sprint Total (s/kgFFM) 0.020* -0.118 1.392 0.064 -0.094 0.884 
Total Handgrip (kg) 0.029 0.111 1.232 0.046 0.102 1.040 
IKR knee extension torque (30 °/s) 0.081 0.091 0.828 0.150 0.075 0.563 
IKL knee extension torque (30 °/s) 0.026 0.116 1.346 0.046 0.104 1.082 
IKR knee extension torque (90 °/s) 0.024 0.117 1.369 0.071 0.094 0.884 
IKL knee extension torque (90 °/s) 0.007* 0.139 1.932 0.024 0.117 1.369 
IKR knee extension torque (180 °/s) 0.045 0.104 1.082 0.128 0.079 0.624 
IKL knee extension torque (180 °/s) 0.020 0.121 1.464 0.064 0.096 0.922 
IKR knee flexion torque (30 °/s) 0.220 0.064 0.410 0.399 0.044 0.194 
IKL knee flexion torque (30 °/s) 0.199 0.067 0.449 0.410 0.043 0.185 
IKR knee flexion torque (90 °/s) 0.137 0.077 0.593 0.303 0.054 0.292 
IKL knee flexion torque (90 °/s) 0.156 0.074 0.548 0.352 0.048 0.230 
IKR knee flexion torque (180 °/s) 0.064 0.096 0.922 0.185 0.069 0.476 
IKL knee flexion torque (180 °/s) 0.084 0.090 0.810 0.226 0.063 0.397 
IKR elbow extension torque (30 °/s) 0.009* 0.136 1.850 0.021 0.120 1.440 
IKL elbow extension torque(30 °/s) 0.009* 0.135 1.823 0.024 0.117 1.369 
IKR elbow extension torque (90 °/s) 0.177 0.071 0.504 0.225 0.063 0.397 
IKL elbow extension torque (90 °/s) 0.032 0.111 1.232 0.046 0.104 1.082 
IKR elbow extension torque(180 °/s) 0.001* 0.166 2.756 0.003* 0.153 2.341 
IKL elbow extension torque (180 °/s) 0.028 0.114 1.300 0.04 0.107 1.145 
IKR elbow flexion torque (30 °/s) 0.014* 0.128 1.638 0.033 0.111 1.232 
IKL elbow flexion torque (30 °/s) 0.026 0.115 1.323 0.063 0.096 0.922 
IKR elbow flexion torque (90 °/s) 0.292 0.055 0.303 0.451 0.039 0.152 
IKL elbow flexion torque (90 °/s) 0.121 0.080 0.640 0.199 0.067 0.449 
IKR elbow flexion torque (180 °/s) 0.456 0.039 0.152 0.536 0.032 0.102 
IKL elbow flexion torque (180 °/s) 0.009* 0.135 1.823 0.019 0.121 1.464 
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Table 6 - Pearson's correlation coefficient results for MYLK1-AS1 copy number and quantitative 
variables before and after correction for subgroup. Significant (p<0.05) values are highlighted in bold. 
Values marked by * have a p-value lower than the acceptable alpha value according to the BH correction. 
kgFFM; kilogram of fat free mass IKR, isokinetic right; IKL, isokinetic left 
Trait 
MYLK-AS1 
Without Group Correction With Group Correction 
p-value Coefficient 
R
2
 
(%) 
p-value Coefficient 
R
2
 
(%) 
Number of pull-ups 0.807 0.012 0.014 0.133 0.077 0.593 
Counter movement jump height (cm) 0.795 0.013 0.017 0.869 0.008 0.006 
Static jump height (cm) 0.583 0.028 0.078 0.575 0.028 0.078 
Sprint 0-10 (s/kgFFM) 0.913 -0.006 0.004 0.918 0.005 0.003 
Sprint 10-20 (s/kgFFM) 0.849 -0.010 0.010 0.934 -0.004 0.002 
Sprint 20-30 (s/kgFFM) 0.731 -0.017 0.029 0.781 -0.014 0.020 
Sprint Total (s/kgFFM) 0.843 -0.010 0.010 0.952 -0.003 0.001 
Total Handgrip (kg) 0.272 0.056 0.314 0.412 0.042 0.176 
IKR knee extension torque (30 °/s) 0.911 0.006 0.004 0.953 -0.003 0.001 
IKL knee extension torque (30 °/s) 0.094 0.087 0.757 0.100 0.086 0.740 
IKR knee extension torque (90 °/s) 0.768 0.015 0.023 0.924 0.005 0.003 
IKL knee extension torque (90 °/s) 0.949 0.003 0.001 0.849 -0.010 0.010 
IKR knee extension torque (180 °/s) 0.699 0.020 0.040 0.890 0.007 0.005 
IKL knee extension torque (180 °/s) 0.571 -0.029 0.084 0.379 -0.046 0.212 
IKR knee flexion torque (30 °/s) 0.675 -0.022 0.048 0.556 -0.031 0.096 
IKL knee flexion torque (30 °/s) 0.806 -0.013 0.017 0.696 -0.020 0.040 
IKR knee flexion torque (90 °/s) 0.995 0.001 0.001 0.862 -0.009 0.008 
IKL knee flexion torque (90 °/s) 0.859 -0.009 0.008 0.730 -0.018 0.032 
IKR knee flexion torque (180 °/s) 0.537 0.032 0.102 0.618 0.026 0.068 
IKL knee flexion torque (180 °/s) 0.619 0.026 0.068 0.696 0.020 0.040 
IKR elbow extension torque (30 °/s) 0.967 -0.002 0.000 0.750 -0.017 0.029 
IKL elbow extension torque(30 °/s) 0.894 -0.007 0.005 0.775 -0.015 0.023 
IKR elbow extension torque (90 °/s) 0.986 -0.001 0.000 0.955 -0.003 0.001 
IKL elbow extension torque (90 °/s) 0.869 0.009 0.008 0.947 0.003 0.001 
IKR elbow extension torque(180 °/s) 0.407 0.043 0.185 0.433 0.041 0.168 
IKL elbow extension torque (180 °/s) 0.429 0.041 0.168 0.457 0.039 0.152 
IKR elbow flexion torque (30 °/s) 0.924 0.005 0.003 0.895 -0.007 0.005 
IKL elbow flexion torque (30 °/s) 0.984 0.001 0.000 0.804 -0.013 0.017 
IKR elbow flexion torque (90 °/s) 0.968 -0.002 0.000 0.749 -0.017 0.029 
IKL elbow flexion torque (90 °/s) 0.955 -0.003 0.001 0.734 -0.018 0.032 
IKR elbow flexion torque (180 °/s) 0.628 -0.025 0.063 0.550 -0.031 0.096 
IKL elbow flexion torque (180 °/s) 0.841 -0.010 0.010 0.686 -0.021 0.044 
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3.4 Subgroup copy number associations with quantitative 
variables. 
The subgroup corrected correlations of MYLK1 (Table 5) indicates that there are 
differences between the subgroups therefore, all of the subgroups were individually examined 
for correlations between MYLK1 copy number and phenotypes associated with strength and 
power performance. An increased copy number in STP is associated with increases in the 
jump performance, handgrip, isokinetic test performance and sprinting performance. 
However, after the BH correction only static jump and isokinetic performance remain 
significant (Table 7). The strength of the correlations is stronger in STP compared to when 
the whole cohort is examined together as seen by a higher percentage of the variance being 
explained (Table 7). In the control group, only one individual has a deviation in copy number 
away from two therefore accurate correlations could not be performed and no associations are 
found in END (data presented in Appendix D). There were no significant subgroup corrected 
or uncorrected correlations for MYLK-AS1, therefore the subgroups were not investigated 
for correlations between copy number and performance in the strength and power tests. 
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Table 7 - Pearson's correlation coefficient results between STP for MYLK1 copy number and 
quantitative variables. Correlations with p<0.05 are highlighted in bold and values marked by * have a p-
value lower than the acceptable alpha value according to the BH correction. kgFFM; kilogram of fat free 
mass IKR, isokinetic right; IKL, isokinetic left 
Trait 
MYLK1 CN SSP associations 
p-value Coefficient R
2
 (%) 
Number of pull-ups 0.125 0.141 1.988 
CMJ height (cm) 0.045 0.184 3.386 
Static jump height (cm) 0.022* 0.214 4.580 
Sprint 0-10 (s/kgFFM) 0.032 -0.197 3.881 
Sprint 10-20 (s/kgFFM) 0.038 -0.192 3.686 
Sprint 20-30 (s/kgFFM) 0.091 -0.157 2.465 
Sprint Total (s/kgFFM) 0.043 -0.186 3.460 
Total Handgrip (kg) 0.022 0.21 4.410 
IKR knee extension torque (30 °/s) 0.361 0.087 0.757 
IKL knee extension torque (30 °/s) 0.204 0.121 1.464 
IKR knee extension torque (90 °/s) 0.073 0.169 2.856 
IKL knee extension torque (90 °/s) 0.044 0.19 3.610 
IKR knee extension torque (180 °/s) 0.07 0.171 2.924 
IKL knee extension torque (180 °/s) 0.038 0.196 3.842 
IKR knee flexion torque (30 °/s) 0.721 0.034 0.116 
IKL knee flexion torque (30 °/s) 0.6 0.05 0.250 
IKR knee flexion torque (90 °/s) 0.506 0.063 0.397 
IKL knee flexion torque (90 °/s) 0.496 0.065 0.423 
IKR knee flexion torque (180 °/s) 0.217 0.118 1.392 
IKL knee flexion torque (180 °/s) 0.325 0.094 0.884 
IKR elbow extension torque (30 °/s) 0.029 0.208 4.326 
IKL elbow extension torque (30 °/s) 0.06 0.178 3.168 
IKR elbow extension torque (90 °/s) 0.223 0.118 1.392 
IKL elbow extension torque (90 °/s) 0.087 0.163 2.657 
IKR elbow extension torque (180 °/s) 0.003* 0.279 7.784 
IKL  elbow extension torque (180 °/s) 0.065 0.175 3.063 
IKR elbow flexion torque (30 °/s) 0.046 0.188 3.534 
IKL  elbow flexion torque (30 °/s) 0.04 0.191 3.648 
IKR elbow flexion torque (90 °/s) 0.35 0.089 0.792 
IKL  elbow flexion torque (90 °/s) 0.095 0.157 2.465 
IKR elbow flexion torque (180 °/s) 0.597 0.051 0.260 
IKL  elbow flexion torque (180 °/s) 0.007* 0.254 6.452 
 
The phenotypes associated with strength and power which were found to be correlated 
to MYLK1 copy number were examined in the overall cohort (see Appendix E) and STP (see 
Appendix F) for the percentage difference between copy numbers. The strongest correlations 
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were found for performance in isolated muscles. Overall in the cohort and in STP, the highest 
amount of variance explained is for the isokinetic extension of the elbow at 180 °/s. Overall 
individuals with three copies of MYLK1 were able to produce 38% more force than 
individuals with two copies, while STP with three copies are able to produce 28% more force 
than STP with two copies (Figure 3). 
 
Figure 3 – Mean peak force produced (N*m) for isokinetic right arm extension of the elbow at 180 °/s for 
each copy number in the whole cohort and the STP alone. Copy numbers which do not share the same 
letter are significantly different from each other with each group.  CN;copy number, IKR Ext; isokinetic 
right arm Extension, STP; strength and power athletes. 
 
For performance in the whole body tasks, overall in the whole individuals with three 
copies were able to jump 12% and 32% higher in the static jump than individuals with two 
copies and one copy respectively. Static jump performance indicates that STP with two 
copies are able to jump 36% higher than STP with one copy and a trend existed for STP with 
three copies jumping higher than STP with one copy (p=0.064; Figure 4). Overall in the 
whole cohort, individuals with three copies are 11% quicker per unit of fat free mass at 
sprinting 30m compared to individuals with only two copies. There is a trend for STP with 
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three copies being quicker per unit of fat free mass than STP with one (p=0.062) or two 
(p=0.0791) copies (Figure 5). 
 
Figure 4 - Mean static jump height (cm) for each copy number in the whole cohort and the STP. Copy 
numbers which do not share the same letter are significantly different from each other with each group.  
CN;copy number, STP; strength and power athletes. 
 
Figure 5 - Mean 30 m sprint time (presented as s/kgFFM) as for each copy number in the whole cohort 
and the STP alone. Copy numbers which do not share the same letter are significantly different from each 
other with each group.  CN; copy number, kgFFM; kilograms of fat free mass,  STP; strength and power 
athletes 
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Chapter 4 - Discussion  
4.1 Main Findings 
The current study aimed to investigate if higher MYLK1 copy number and lower 
MYLK-AS1 copy number is associated with athlete status and performance in physiological 
tests associated with strength and power performance in a cohort of athletes and non-athlete 
controls. We report, for the first time, increased copy number of MYLK1 is associated with 
athlete status and improved muscle performance. The main findings of the current study are: 
1) individuals with higher MYLK1 copy number are more likely to be strength and power 
athletes than controls; 2) the highest level of competition achieved is not associated with 
MYLK1 copy number; 3) an increase in MYLK1 copy number is associated with better 
performance in tests indicative of strength and power, across the whole cohort and for STP 
alone; 4) copy number of MYLK-AS1 does not influence athlete status or performance in 
tasks associated with strength and power. 
 
4.2 MYLK1 
4.2.1 Copy number and athlete status 
In the current study, we hypothesised that there would be an overrepresentation of individuals 
with a higher copy number in STP. We demonstrated that individuals with an additional copy 
of MYLK1 are more likely to be a STP than a control (Table 4). A deviation of copy number 
away from two does not confer an added chance of being an END compared to control. 
Taken together, these data suggest that having three copies of MYLK1 provides an advantage 
which predisposes individuals to becoming a STP. Although no other studies have examined 
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the nature of CNVs in athletes and associations with athlete status, several studies have 
associated CNVs with the chance of developing several diseases. There are several diseases 
which have been associated with the alterations of copy number, including neurological 
disorders (Singleton et al., 2003; Sleegers et al., 2006; Weiss et al., 2008; Pankratz et al., 
2011), various forms of cancer (Yang et al., 2013) and several chronic health diseases (Pollex 
& Hegele, 2007; Grayson et al., 2010; Jeon et al., 2010). There are also examples of CNVs 
reducing the risk of health disorders such as obesity (Falchi et al., 2014) and delaying the 
onset of spinal muscular atrophy (Elsheikh et al., 2009). The associations between CNVs and 
disease highlight the fact that alterations in gene copy number can be functional for a range of 
different traits and that consequences can be beneficial or deleterious. The mechanism by 
which CNVs have phenotype consequences and alter disease susceptibility remains to be 
fully understood but is thought to occur through a change in the expression of the affected 
gene (Pollex & Hegele, 2007; Grayson et al., 2010; Yang et al., 2013). Despite this being the 
first study to associate CNVs with athlete status, other forms of genetic variation, namely 
SNPs have been associated with athlete status.  
 
When SNP genotype frequencies of athletes are examined there is an indication that 
there is a genetic predisposition to the trade-off between endurance and power capacity. 
Certain genotypes are over-represented in either strength or endurance athletes which 
indicates individuals are genetically predisposed to perform better in either strength/power or 
endurance-type activity (Yang et al., 2003). ACTN3 is a muscle structural protein involved in 
the stabilization of muscle contractions and is predominantly expressed in fast twitch muscle 
fibres (Yang et al., 2003; Moran et al., 2007; Walsh et al., 2008). The X allele of the R577X 
ACTN3 polymorphism has been shown to render the protein non-existent (Berman & North, 
2010). When the genotype frequencies of R577X are examined, it is found that there is a lack 
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of the X allele and over-representation of the R allele in strength and power athletes including 
Russian power athletes (Druzhevskaya et al., 2008), Greek power athletes (Papadimitriou et 
al., 2008) Finnish sprinters (Niemi & Majamaa, 2005), American strength athletes (Roth et 
al., 2008) and Australian sprint/power athletes (Yang et al., 2003). These studies show that 
genetic variants which affect fast twitch fibres can be overrepresented in a cohort of power 
and strength athletes but not in endurance based athletes as was found in the present study.  
 
In humans, the majority of muscles are comprised of a mixed fibre type composition, 
therefore it has been suggested that individuals may be predisposed to either power or 
endurance phenotypes (Van Damme et al., 2002; Yang et al., 2003). Animal models have 
extensively been used to determine if there is a pre-determined evolutionary trade-off in 
muscle capacity towards either power or endurance phenotypes. In mice a negative 
correlation exists between maximum power output and fatigue resistance of muscles 
suggesting an evolutionary trade-off (Wilson & James, 2004).  In a study examining the 
performance of decathletes, it has been found that performance in the 1500m race is 
negatively correlated with the performance in the 100m, 100m hurdles, shot put and long 
jump (Van Damme et al., 2002). These findings suggest that the performance of decathletes 
is either favoured towards power or endurance and indicate that in humans a trade-off 
between endurance and power capacity does in fact exist. Genetic variants, such as, MYLK1 
copy number may influence the sport in which athletes perform as is indicated by the results 
of the present study. 
 
A potential reason for the overrepresentation of higher MYLK1 copy number in the 
STP but not in the END is because MYLK is predominately expressed in the fast twitch type 
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II muscle fibres rather than slow twitch type I muscle fibres (Zhi et al., 2005; Herring et al., 
2010; Kamm & Stull, 2011). The fibre type distributions of athletes who compete in different 
events have been examined in previous studies (Costill et al., 1976; Zierath & Hawley, 2004). 
It has been found that athletes who perform endurance based events have a higher relative 
percentage of slow twitch fibres and sprinters have a higher percentage of fast twitch fibres 
(Costill et al., 1976). The increased percentage of fast twitch fibres in sprinters is possibly 
because they are the fibres which can produce higher force and velocity, which are required 
to compete in short distance, high power output events (Zierath & Hawley, 2004). Therefore, 
it is expected that in our cohort the greatest distribution of fast twitch fibres will be found in 
the STP and these individuals will be the most affected by functional genetic variation in the 
MYLK1 gene.  
 
4.2.2 Level of Competition 
In our cohort of athletes when the highest level of competition achieved is examined 
for associations with MYLK1 copy number, only the regional athletes differ from the 
controls for increased copy number. If MYLK1 copy number was associated with the highest 
level of competition achieved then we would expect to find that the higher classifications of 
athletes (international and national standard) would differ from the lower levels of athletes 
(regional and other) and controls. Given the lack of associations across different competition 
levels, our results indicate a gain in copy number is associated with the selection of sport 
because of natural ability, although there might not be any further advantage gained from 
training. 
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Genetic variants for power and endurance based sports have shown increased 
frequencies of one allele in higher level athletes. In a study looking at 10 common genotypes 
which have been associated with endurance performance it is found that individuals with a 
higher number of ‘endurance alleles’ are more likely to be an elite athletes than non-elite 
athletes (Ahmetov et al., 2009). Another study has found the frequency of the Gly482 allele 
of the PPARGC1A gene was 20% higher in top-level athletes compared to national level 
athletes (Eynon et al., 2010). Associations also have been made with genotype frequencies in 
elite and non-elite power orientated athletes. In a cohort of elite Australian power athletes 
(Yang et al., 2003) and a cohort of Finnish sprinters (Niemi & Majamaa, 2005), the XX 
genotype of ACTN3 R577X is not detected. These studies strengthen the theory that certain 
genotypes may predispose athletes to certain athletic disciplines since higher level athletes 
show an increased allele frequency compared to both controls and lower level athletes. 
Despite these previous findings that a range of genes have been associated with elite athlete 
status; MYLK1 copy number does not associate with elite athletic performance in the present 
study. 
 
A potential reason for the lack of findings in the level of competition of the athletes is 
that both higher and lower MYLK1 copy number are rare variants and therefore found at a 
much lower frequency than the genetic variants examined in other studies. A gain in copy 
number was only found in our cohort at 2% (5% in STP) and only 12 individuals (3%) in the 
cohort had deviations away from a normal copy number of two (Table 3). In previous studies 
considering the highest level of competition achieved, the minor allele frequency has been 
greater than 5% in all cases and is typically around 30% (Yang et al., 2003; Niemi & 
Majamaa, 2005; Ahmetov et al., 2009; Eynon et al., 2010). Another potential reason for 
MYLK1 copy number associating with STP but not level of competition is that the overall 
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ability of an athlete is determined through various genetic polymorphisms and environmental 
factors (Pitsiladis et al., 2013). Environmental factors such as opportunity, economic 
possibility and social support are all involved in the determination of elite level athletes 
(Lucía et al., 2010). The sport in which the athlete competes also needs to be considered for 
the level of competition achieved; regional athletes of one sport may actually be a better 
overall calibre athlete than a national level athlete of a different sport but competition for 
places in the national squad may be the limiting factor. Therefore highest level of competition 
achieved may not be the best measure for the effect of the genetic variants because it may not 
be representative of overall ability. 
 
4.2.3 Quantitative data 
The inclusion of the quantitative phenotype data strengthens the study because it 
allows the investigation of the impact of copy number on different aspects of performance 
which provides more conclusive findings than the qualitative nature of athlete status and level 
of competition data. Positive correlations were found between MYLK1 copy number and 
measures of strength and power in both isolated muscles and dynamic movements. The 
correlations were absent or weakened after correction for subgroup. Therefore, the 
differences between groups explain some of the phenotypic consequences between copy 
number associations. Between-group differences are not surprising because of the different 
training strategies required for STP and END and a lack of training performed by the 
controls. Each of the athletic subgroups was examined individually for the correlations 
between copy number and quantitative traits. Only one of the controls had a deviation away 
from a copy number of two. Therefore, correlations were not performed within this group. 
Several correlations were found in the STP for both isolated and dynamic muscle 
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performance (Figure 3-5), whereas no associations were found in END (Appendix D). The 
correlations in STP were expected because of the overrepresentation of STP with three copies 
of MYLK1. The existence of correlations in STP and not END suggest that it may be the type 
II muscle fibres which are affected or that the effect of the CNV is increased through training 
specific to STP. 
 
Different polymorphisms have been associated with different aspects of performance, 
such as response to training or maximal force production (Kostek et al., 2010; Ahmetov & 
Fedotovskaya, 2012). Previous MYLK1 SNP studies have identified a potential role of 
MYLK1 variation in the determination of baseline strength levels (Clarkson et al., 2005) 
which could suggest that MYLK1 may make individuals stronger and therefore more likely 
to perform sports related to power rather than endurance. The previous associations with 
MYLK1 have only been examined in isolated muscle groups therefore the effect on 
physiological performance is yet unknown (Clarkson et al., 2005). The current study 
associates increased copy number with both performance in isolated muscle groups and 
performance in whole body movements physiologically relevant to performance. The 
findings with phenotypes associated with isolated muscles (Figure 3), such as dynamometry 
measures, allow the determination of peak force, however these are not physiologically 
relevant measures of performance. Individuals with three copies of MYLK1 were able to 
jump higher than individuals with one or two copies. An advantage also is seen in sprinting 
performance over 30m where the individuals with three copies are quicker per unit of fat free 
mass than the individuals with only two copies. MYLK1 copy number is shown to explain a 
lower percentage of the variance in these whole body traits; however, this is expected 
because these whole body movements consist of the contractions of several muscles, 
therefore external factors have more of a chance to affect them. 
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Two SNPs in MYLK1 have previously been associated with muscle performance in 
diseased cohorts (Clarkson et al., 2005; Deuster et al., 2013) which supports the findings of 
the present study. The T allele of C49T of MYLK1 has been associated with increased 
baseline strength in a clinical cohort (Clarkson et al., 2005). Unpublished work in this cohort 
of athletes reports associations with the C allele of C49T and increased force production. The 
differences in the allele which is associated with strength could be explained by the different 
cohorts that were examined. The other SNP which has been associated with muscle 
performance phenotypes is C37885A. The C allele of C37885A has been shown to have a 
protective effect on strength loss following muscle damaging exercise (Clarkson et al., 2005). 
. Unpublished work in the present cohort has associated the C allele with increased peak force 
in isokinetic arm tests which supports the findings in the literature of the C allele producing 
an advantageous muscle performance phenotype. The SNP studies support our findings that 
genetic variants of MYLK1 are associated with performance in quantitative muscle 
performance traits.  
 
With SNPs typically only explaining 1-2% of the variance in muscle strength between 
individuals, a large percentage of the variance remains unexplained (Kostek et al., 2010). The 
CNV of MYLK1 in this study has been shown to explain at most 3% of the variance between 
individuals in the cohort. When the variance in the STP is examined, we demonstrate that 
over 7% of the performance in high speed elbow extension between individuals is explained 
by differences in copy number. The results indicate that CNVs may contribute more too 
phenotypic traits than SNPs which is expected because SNPs only affect one nucleotide; 
whereas CNVs can influence millions of nucleotides and thus can have more drastic effects. 
More studies on CNVs and athletic performance are required to confirm the associations 
before a statement on the size of the effect compared to SNPs can be made.  
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4.2.4 Mechanisms 
Increased MYLK1 copy number is thought to associate with increased performance in 
strength and power phenotypes through an increase in the expression of the MYLK1 gene. 
Despite MYLK1 being expressed in skeletal muscle, skeletal muscle RLC is not a good 
substrate for MYLK1 because of differences in substrate properties (Kamm & Stull, 2001). In 
MYLK2 ablated mice the phosphorylation of the RLC still occurs which indicates there may 
be a redundancy mechanism between skMLCK and smMLCK despite a lack of increased 
MYLK1 expression as a result (Takashima, 2009). The phosphorylation of the RLC in 
MYLK2 ablated mice supports this because it indicates that other kinases are able to 
phosphorylate skeletal muscle RLC and  will have the same effect on enhanced rate of force 
development as MYLK2(Zhi et al., 2005). In cardiac tissue the smMLCK is expressed at a 
lower level than cmMLCK and despite differences in substrate properties, smMLCK is still 
capable of phosphorylating the cardiac muscle RLC. This has led to the suggestion that 
following the decline in cmMLCK expression smMLCK may act as a backup kinase 
(Josephson et al., 2011). We speculate that the increased copy number of MYLK1 leads to 
increased expression of smMLCK which acts together with the skMLCK to produce 
increases in the rate of force development and force potentiation. 
 
In humans, RLC phosphorylation has been linked to post-activation potentiation 
(PAP) of type II muscle fibres (Lorenz, 2011). The previous contractile history of the muscle 
has a large effect on the ability of the muscle to generate force and enhanced contractile 
response is thought to occur following high intensity contraction (Docherty & Hodgson, 
2007). PAP results in increased force and rate of force development which has led to 
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suggestions that the molecular mechanism responsible for the enhanced contractile response 
is increased phosphorylation of the RLC. The phosphorylation of the RLC by MLCK occurs 
at a rapid rate and the dephosphorylation is a slower process, therefore it is thought that prior 
contractions function to prime the muscle for future contractions and subsequently increase 
the rate of force development and peak isometric twitch force (Zhi et al., 2005). Greater PAP 
has been consistently observed in trained individuals compared to untrained individuals (Chiu 
et al., 2003) and amongst individuals with a higher percentage of type II muscle fibres 
(Hamada et al., 2000). Therefore we speculate that the increase in MYLK1 copy number will 
lead to increased expression of MYLK1 and subsequently increased phosphorylation of the 
RLC in skeletal muscle leading to elevated PAP. A potential reason that increased copy 
number is found more often in STP is that they are the thought to be the individuals with the 
greater distribution of type II muscle fibres and therefore will gain the greatest advantage 
from PAP. 
 
4.3 MYLK-AS1 
 It was hypothesised that an increase in the MYLK-AS1 gene would lead to detriments 
in athletic performance. No associations were found between MYLK-AS1 copy number and 
athlete status or highest level of competition achieved. These findings indicate that alterations 
in MYLK-AS1 copy number do not confer any advantage or disadvantage to athletic 
performance. When the quantitative phenotype data for traits associated with strength and 
power are examined, it is shown that there are no positive or negative correlations with 
MYLK-AS1 copy number and these phenotypes. Taken together, these data indicate that 
alterations in MYLK-AS1 copy number is not involved in athletic performance related to 
strength and power. It has been shown that most CNVs have some form of effect on 
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expression which usually translates to alterations in the final protein content (Stranger et al., 
2009; Tang & Amon, 2013). In the present study, we do not find any associations between 
MYLK-AS1 copy number and function; however that does not mean that there is no 
functional consequence. The results suggest that alterations in copy number of MYLK-AS1 
does not influence skeletal muscle phenotypes related to strength and power. The lack of 
functional consequences of CNVs of MYLK-AS1 suggests that antisense genes may not 
always influence the function of the associated sense genes.  
 
 Antisense genes are found across a range of different organisms (Dahary et al., 2005) 
and at a higher frequency with genes which have multiple isoforms. It has been suggested 
that antisense transcription has been conserved through evolution to influence the splicing of 
the associated sense gene (Morrissy et al., 2011). There is some evidence that antisense genes 
can function to alter the splicing pattern of sense transcripts (Hastings et al., 1997; Annilo et 
al., 2009). Sense and antisense transcript interaction usually affects both the expression and 
splicing of the sense gene; however it has been shown for a small number of genes that 
antisense can affect only expression or splicing alone (Morrissy et al., 2011). The formation 
of double stranded RNA is the expected mechanism which leads to alternative splicing 
patterns. Antisense transcripts have been found to bind to the sense transcript to mask the 
splice sites of the THRA gene (Hastings et al., 1997). The findings suggest that it is a 
consequence of sequence overlap between the sense and antisense transcripts which causes 
the alternative splicing. To determine the importance of sequence overlap for antisense 
mediated splicing, it has been examined if regions with antisense overlap are more likely to 
reveal antisense mediated splicing than regions without overlapping sequences. There is a 2.5 
fold increase in regions with overlapping sense and antisense sequences suggesting that 
overlapping sequences are an important factor in antisense mediated splicing (Morrissy et al., 
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2011). As is shown in Figure 2, there is a region of overlap between the MYLK1 and MYLK-
AS1 genes. Therefore, variation in MYLK-AS1 may not affect the expression of MYLK1 
rather regulate the splicing pattern; hence there may not be any phenotypic consequence on 
muscle strength and power of CNVs of MYLK-AS1. 
 
 The MYLK1 gene encodes at least three products, including nonmuscle MYLK1, 
smooth muscle MYLK1 and Telokin, which are produced through the use of different 
promoters rather than alternative splicing (Herring et al., 2006). Alternative splicing has been 
shown to create multiple isoforms of nonmuscle MYLK1 transcripts (Lazar & Garcia, 1999; 
Hong et al., 2011). If MYLK1 sense and antisense gene interactions function to only affect 
the splicing of nonmuscle MYLK1 then this may explain why there are no functional impacts 
on muscle strength and power phenotypes. It is possible that the findings with MYLK1 copy 
number are because of increased expression of smooth muscle MYLK1 and interactions with 
skeletal muscle to affect the strength and power phenotypes. The alteration of MYLK-AS1 
expression may influence the splice pattern of the nonmuscle MYLK1 isoform, therefore 
potentially having no impact on skeletal muscle strength and power phenotypes. 
 
4.4 Summary 
4.4.1 Combined findings 
 Overall, we have demonstrated that higher copy number of MYLK1 leads to 
associations with athlete status and improved performance in physiological tests associated 
with strength and power. The associations between copy number and quantitative phenotypes 
are weakened upon correction for subgroup which suggests that the type of training 
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performed by the athletes has an effect on the phenotypic consequences of MYLK1 copy 
number alterations. On assessment of the subgroups, we find only one control participant had 
a deviation in copy number and that there are no associations in END. Higher copy number in 
the STP is shown to associate with increased performance in tests which isolate specific 
muscle groups and tests which rely on whole body movements. Increased MYLK-AS1 copy 
number was hypothesised to be detrimental to muscle performance, however we fail to find 
any associations between copy number in this gene and either athlete status or performance in 
physiological tests associated with strength and power. The lack of association with athletic 
performance in MYLK-AS1 suggests that the function of the antisense gene is not only the 
regulation of MYLK1 expression. 
 
 The current study has found that there are different phenotypic consequences between 
CNVs of MYLK1 and MYLK-AS1. Despite the sequence of the two genes overlapping 
(Figure 2), an alteration in copy number in one of the genes is not always met with alteration 
in copy number in the other. The different phenotypic consequences of copy number on the 
target genes indicates different copy number events must be detected in the two genes, 
otherwise the associations between athlete status and quantitative phenotypes would be 
identical. It was originally hypothesised that if there was a gain of MYLK1 or loss of MYLK-
AS1 that this would increase MYLK1 expression and result in increased strength and power 
and the opposite would be true of a loss in MYLK1 or gain in MYLK-AS1 copy number. We 
only detect these associations with MYLK1 which suggests that the expected alteration of 
MYLK1 expression in skeletal muscle by deviations of copy number does not occur in 
MYLK-AS1. These findings suggest that the copy number variants investigated affect 
separate mechanisms for MYLK1 and MYLK-AS1. 
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 It is thought that higher MYLK1 copy number exerts functional effects on athletic 
performance through increased expression of MYLK1. We suggest that the increased 
expression of MYLK1 will lead to increases in strength and power phenotypes through a 
compensatory mechanism between MYLK1 and MYLK2. This compensation is thought to 
exist because of the ubiquitous expression of MYLK1 in all types of tissue and evidence 
there is still RLC phosphorylation in skeletal muscle of mice with ablated MYLK2. It has 
been shown that phosphorylation of the RLC leads to increased rate of force production and 
force potentiation. The lack of association with MYLK-AS1 is thought to be explained by the 
fact that not all antisense genes are involved in gene expression. It has been shown that some 
antisense genes function to alter the splicing of the associated sense gene (Morrissy et al., 
2011). With evidence of alternative splicing of MYLK1 to create several isoforms of the 
nonmuscle MYLK1 protein (Hong et al., 2011), we suggest that potentially the role of the 
MYLK-AS1 gene may be to control the splicing and therefore CNVs of this gene would be 
unlikely to affect skeletal muscle phenotypes.  
 
 The results of the present study have identified, for the first time, associations 
between CNVs and muscle performance in an athletic cohort. These results taken with 
previous SNP data on MYLK1 (Clarkson et al., 2005)suggest that variation in this gene is 
functionally involved in the determination of muscle strength and power in both athletic and 
clinical populations. Replication of these findings in other cohorts and determination of the 
mechanisms behind these associations are required to understand the health implications of 
MYLK1 genotypes.  
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4.4.2 Strengths 
The inclusion of different athletic subgroups in the GELA cohort allowed the 
investigation of the impact of CNVs on different types of training. The quantitative 
phenotype data both of whole body movements and isolated muscles allowed the examination 
of the functional effects these variants can have on performance. Identification of specific 
aspects of performance that are affected by CNVs allows the inference of potential 
mechanism underlying the associations between gene copy number and performance. The use 
of the multicopyType-it CNV Reference Probe assay instead of a single reference gene adds 
to the validity of the copy number determination in the current study. The Database of 
Genomic Variants (MacDonald et al., 2014) has shown that the typical reference genes TERT 
and RPPH1 have whole gene spanning CNVs which could affect copy number determination 
in target genes (Conrad et al., 2010; Xu et al., 2011). If there is a CNV on one of the loci of 
the Type-it CNV reference assay then the copy number determination will only be altered by 
a fraction, therefore, the effect will be greatly reduced compared to traditional reference 
assays. The use of fluorescently labelled probes rather than fluorescent dyes increases the 
reliability of copy number determination because it has been determined that fluorescent dyes 
can overestimate copy number in long amplicons and AT rich sequences (Colborn et al., 
2008). 
 
4.4.3 Limitations 
As with all other studies there are limitations associated with the present study. It has 
been shown that somatic mosaicism of CNVs can occur where within different tissues there is 
a different copy number (Piotrowski et al., 2008). The CNVs were examined in blood 
leucocytes, however the tissue that we are interested in is skeletal muscle. If there are 
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discrepancies in copy number of MYLK1 between leucocytes and skeletal muscle cells, then 
it would be difficult to detect associations with strength and power phenotypes. Such 
discrepancies could also suggest that a non-skeletal muscle mechanism causes the associated 
increases in power and strength. While the investigation of muscle specific mechanisms 
would undoubtedly offer an interesting insight to the relationship between CNV and 
performance, the invasive nature of muscle biopsies can lead to the loss of training, which 
can make it difficult to recruit athletes. Thus, collection of skeletal muscle biopsies was not 
possible with the current cohort. Nonetheless, by using, blood samples we were able to study 
a much larger cohort than would otherwise have been possible which provides greater power 
to detect genomic variants. 
 
4.4.4 Future work 
Future studies should aim to replicate the findings of this study in a different cohort of 
athletes and controls to validate the findings in MYLK1 copy number with associations to 
strength and power phenotypes. These studies should also examine other CNVs in genes 
which have been previously associated with muscle phenotypes to identify if other CNVs are 
associated with athletic performance. Studies should also include measures of the expression 
of target genes in skeletal muscle to confirm if increases in copy number are met with 
concurrent increases in expression. The inclusion of the expression data will provide some 
insight to potential mechanisms which underlie the athletic performance phenotypes. Once 
replication of MYLK1 and CNV of other genes have been investigated for associations with 
muscle performance, these polymorphisms can potentially be used to identify individuals at 
risk of developing muscle wasting disorders and metabolic diseases and provide them with 
personalised plans to maximise strength to improve quality of life. 
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Chapter 5 - Conclusion 
In conclusion, CNVs of MYLK1 are found at a higher frequency in STP than in non-
athlete controls. These variants of MYLK1 copy number were found to associate with 
quantitative phenotypes associated with strength and power. These associations explain more 
of the variance in the STP than in the cohort as a whole (~7% and ~3% respectively for 
variance in elbow extension peak torque). Conversely, it was thought that MYLK-AS1 would 
associate with decrements in performance; however, the presence of CNVs of MYLK-AS1 
does not associate with any of the measures of strength and power phenotypes in this study. It 
is thought that the increases with MYLK1 copy number will lead to concurrent increases in 
the expression of MYLK1. The mechanisms underlying the functional changes in muscle 
strength and power phenotypes cannot be identified in the present study. The mechanism 
could potentially be an increased expression of smMLCK which could affect RLC 
phosphorylation in skeletal muscle to increase the rate of force development and peak force. 
The unknown function of the antisense gene in the regulation of protein-coding genes could 
be the reason that the alteration of MYLK-AS1 copy number does not influence strength and 
power phenotypes as was hypothesised. The result of the present study furthers the current 
knowledge of how genetic variants underpin muscle performance. Further studies are needed 
to confirm that variation in MYLK1 is associated with increased strength and power. If these 
findings can be replicated, MYLK1 could potentially be used as a target to maintain an 
individual’s strength for improvements in athletic performance and the treatment of muscle 
wasting disorders.  
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Appendix A – The total number of athletes and number of athletes within each 
level of competition who perform each of the sports.  
 
Group Sport 
Total 
number 
International National Regional Other 
S
S
P
 
Combat Sport 23 4 13 3 3 
Weightlifter 20 0 1 4 15 
Sprint Runner 13 0 5 5 3 
Sprint Swimmer 3 0 2 1 0 
Field Athlete 5 0 4 0 1 
Team sport player 53 0 18 29 6 
High-diver 1 0 1 0 0 
Motocross-rally Driver 
Gymnasts 
1 
7 
0 
0 
1 
5 
0 
2 
0 
0 
E
N
D
 
Cyclists 10 1 6 1 2 
Distance Runner 49 0 29 14 6 
Distance Walker 4 3 1 0 0 
Triathlete 5 0 3 2 0 
Rower 1 1 0 0 0 
Skiers 3 1 1 1 0 
Orienteers 10 2 7 1 0 
Modern Pentathletes 2 2 0 0 0 
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Appendix B – Details on the physiological tests selected for phenotype 
determination 
 
Handgrip strength 
General upper body strength was tested with a commonly used handgrip test. A Hydraulic 
Hand Dynamometer (Model J00105, Lafayette Instrument Company, Lafayette, IN) was used 
to measure grip strength. Subjects were seated at the table with knees and elbow of the tested 
arm flexed to 90°. Each subject was permitted three trials with each hand. The dynamometer 
was adjusted to the individual hand size, and before each trial subjects used a towel to dry 
their palms to ensure a good grip. On each attempt, subjects were required to squeeze the 
dynamometer with maximal effort for two seconds. A rest period of 30 s was allowed 
between trials, and the best of the trials was recorded for each hand and totalled together to 
generate the total handgrip strength. 
 
Isokinetic dynamometry. Knee and elbow flexion and extension peak torques were measured 
on  isokinetic dynamometer (Biodex Pro3, USA) at 30, 90 and 180 °/s. Each set consisted of 
3 repetitions of consecutive flexion/extensions cycles of  maximal efforts throughout the 
range of motion. Sets always started with 30 °/s, and were followed by 90 °/s and then 180 
°/s. Each of the sets was separated by a 90 s rest period, subjects started with right leg, 
followed by left leg, then right arm and left arm.  
 
Pull-ups. A standard rigid gymnastic bar (2.5 cm diameter) at a height of 2.6 m from the 
ground was used. Participants were instructed to give their maximum efforts to perform as 
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many pull-ups as possible at their preferred speed but without passively hanging on the bar. 
The test was carefully supervised by a trained individual. 
 
Counter movement jump and static jump. Performing counter movement jump, the 
participant were required to squat down quickly to 90° angle at the knee and immediately 
jump up as high as possible. Performing static jump, aftera 3–5 s at still squat with 90° knee 
angle the participant had to jump as high as possible  without any additional drop in the 
center of gravity. Counter movement jump attempts always preceded static jumps attempts. 
During jumps of both modes, arms were held akimbo, and the knee angles as well as the 
vertical modes of the jumps were inspected visually by a single researcher. A rest period of at 
least 30 s between jumps was used. Jumps were performed on a portable multicomponent 
force platform (Kistler, type 9286AA, Switzerland), which measured the vertical component 
of ground reaction force at a frequency of 1000 Hz. Kistler BioWare software, with 
Performance module (version 3.06c), was used to collect and analyze force data during the 
jumps. Height (cm) of the jump was calculated using the following formula: Height = 
122.625 ´ (Tf)
2
, where Tf = flight time (s). After practicing for 2 trials on each jump mode, 
three test trials of each mode were allowed, and the highest jump of each mode was taken for 
subsequent analysis. 
30 m sprint. The sprint run was performed on a smooth hard surface. Four fixed field 
(without reflectors) electronic photocells (NewTest Powertimer; Oulu, Finland) for time 
measurement were positioned exactly at 0 m, 10 m, 20 m and 30 m at a height of 1 m, i.e., 
time for three consecutive 10 m sprint runs were recorded with an accuracy of 0.001 seconds. 
Three trials were allowed, with the recovery of 2-3 min in between. Data of the best 30 m 
performance were taken for the analysis. 
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Apendix C – Concentrations of the DNA samples used in the present study 
 
Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
KN001 12.79 KN043 17.35 KN082 15.69 KN123 18.13 
KN002 16.24 KN044 26.64 KN083 15.44 KN124 20.03 
KN003 15.53 KN045 29.65 KN085 21.15 KN125 21.78 
KN004 20.7 KN046 16.89 KN086 18.04 KN126 18.83 
KN005 15.93 KN047 10.84 KN087 24.39 KN127 19.28 
KN006 10.5 KN048 14.9 KN088 12.08 KN128 17.9 
KN007 15.3 KN049 13.17 KN089 16.31 KN129 22.6 
KN008 9.44 KN050 15.297 KN090 20.21 KN130 24.43 
KN009 13.54 KN051 8.6 KN091 16.2 KN131 17.17 
KN010 25.66 KN052 10.92 KN092 36.62 KN132 23.66 
KN011 22.44 KN053 11.8 KN093 26.74 KN133 21.41 
KN012 31.61 KN054 19.46 KN094 18.34 KN134 11.61 
KN013 11.4 KN055 19.01 KN095 22.04 KN135 14.03 
KN015 15.33 KN056 15.23 KN096 26.61 KN137 15.17 
KN017 17.93 KN057 17.09 KN097 19.58 KN138 18.36 
KN020 12.29 KN058 27.29 KN098 22.75 KN139 15.97 
KN021 18.36 KN059 19.64 KN099 18.16 KN140 19.84 
KN022 23.23 KN060 16.53 KN100 30.52 KN142 16.14 
KN023 11.4 KN061 21.92 KN101 28.97 KN143 16.26 
KN024 18.76 KN062 26.91 KN102 21.42 KN145 8.48 
KN025 11.66 KN063 16.97 KN103 28.99 KN146 11.53 
KN026 10.46 KN064 22.78 KN104 19.92 KN147 18.08 
KN027 20.97 KN065 20.65 KN105 23.86 KN148 27.04 
KN028 5.71 KN066 15.23 KN106 13.72 KN149 20.8 
KN029 19.24 KN067 23.79 KN107 19.45 KN150 26.25 
KN030 19.42 KN068 20.13 KN108 31.78 KN152 14.35 
KN031 8.71 KN069 15.85 KN110 20.64 KN153 13.64 
KN032 16.83 KN070 20.62 KN111 27.57 KN154 13.7 
KN033 17.41 KN071 28.32 KN112 14.06 KN155 13.93 
KN034 14.96 KN072 24.34 KN113 18.52 KN156 10.21 
KN035 12.44 KN074 24.16 KN114 28.95 KN157 16.55 
KN036 16.64 KN075 17.79 KN115 21.33 KN158 15.61 
KN037 17.55 KN076 35.7 KN117 9.62 KN159 21.67 
KN038 24.71 KN077 23.39 KN118 22.03 KN160 21.44 
KN039 19.67 KN078 20.42 KN119 29.31 KN161 13.27 
KN040 16.37 KN079 13.99 KN120 17.21 KN162 15.88 
KN041 11.18 KN080 16.99 KN121 18.34 KN163 16.23 
KN042 17.08 KN081 27.55 KN122 18.6 KN164 18.63 
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Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
KN165 29.25 KN208 24.47 KN258 27.103 KN303 23.41 
KN166 20.22 KN209 19.95 KN259 17.888 KN304 11.566 
KN167 24.97 KN210 23.16 KN260 14.453 KN305 26.293 
KN168 25.08 KN211 19.9 KN262 11.531 KN306 10.408 
KN169 19.13 KN212 19.19 KN263 10.428 KN307 15.833 
KN170 25.21 KN213 23.37 KN264 13.77 KN308 13.516 
KN171 20.06 KN215 22.13 KN265 10.405 KN309 17.873 
KN172 11.12 KN216 26.78 KN266 21.706 KN310 14.699 
KN173 16.43 KN217 27.02 KN267 24.038 KN311 13.649 
KN174 30.52 KN218 19.35 KN268 16.28 KN313 9.191 
KN176 21.04 KN219 22.00 KN269 16.76 KN314 16.789 
KN177 14.43 KN220 19.80 KN270 12.075 KN315 11.396 
KN178 19.19 KN223 28.65 KN271 11.383 KN316 20.078 
KN179 23.38 KN225 33.54 KN272 13.566 KN317 10.955 
KN180 15.13 KN226 19.04 KN273 15.844 KN318 11.531 
KN181 17.04 KN227 24.82 KN274 24.709 KN319 12.623 
KN182 19.31 KN229 24.28 KN276 17.014 KN320 10.465 
KN183 15.76 KN230 18.02 KN277 19.277 KN321 20.263 
KN184 24.46 KN231 31.16 KN278 18.072 KN322 22.458 
KN185 22.48 KN232 19.38 KN279 15.885 KN323 7.078 
KN186 19.79 KN233 19.06 KN280 22.321 KN324 20.201 
KN187 17.61 KN234 13.25 KN281 16.925 KN326 15.706 
KN188 26.82 KN236 26.64 KN282 18.923 KN327 11.383 
KN189 18.33 KN237 14.32 KN284 12.457 KN328 13.172 
KN190 22.37 KN238 14.239 KN285 57.31 KN329 27.863 
KN191 26.47 KN239 17.528 KN286 12.117 KN330 12.629 
KN192 30.87 KN240 14.387 KN287 23.062 KN331 11.526 
KN193 17.53 KN241 14.094 KN288 15.374 KN332 11.566 
KN194 16.63 KN242 20.598 KN289 25.247 KN333 12.596 
KN195 14.97 KN245 18.43 KN290 13.402 KN334 10.408 
KN196 11.91 KN246 22.791 KN291 16.612 KN335 12.522 
KN197 23.98 KN247 19.668 KN292 15.337 KN336 15.833 
KN198 16.46 KN248 10.982 KN294 24.962 KN337 14.155 
KN199 19.87 KN250 13.694 KN295 12.011 KN338 15.706 
KN200 20.4 KN251 27.442 KN296 17.711 KN340 13.552 
KN201 17.81 KN252 13.219 KN297 25.336 KN341 21.163 
KN202 19.6 KN253 18.62 KN298 18.575 KN342 14.751 
KN203 19.09 KN254 15.337 KN299 18.669 KN343 23.611 
KN205 20.02 KN255 17.422 KN300 27.382 KN344 18.112 
KN206 16.13 KN256 15.287 KN301 13.727 KN345 11.566 
KN207 14.16 KN257 18.852 KN302 12.623 KN346 9.31 
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Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
Identifier 
Conc. 
(ng/µL) 
KN347 21.363 KN371 24.023 KN400 10.344 KN429 15.194 
KN348 15.788 KN372 28.48 KN401 12.557 KN430 10.889 
KN349 7.098 KN373 30.507 KN402 17.842 KN431 10.982 
KN350 17.625 KN374 10.282 KN403 15.706 KN433 33.047 
KN351 21.122 KN376 22.708 KN405 24.962 KN434 17.525 
KN352 20.598 KN377 22.747 KN407 16.473 KN435 10.955 
KN353 21.706 KN378 17.525 KN409 18.727 KN436 13.066 
KN354 19.668 KN380 16.358 KN410 15.334 KN437 10.919 
KN355 10.813 KN381 10.8225 KN412 18.51 KN438 12.011 
KN356 35.7955 KN382 28.54 KN414 57.31 KN439 8.666 
KN357 29.5765 KN383 20.93 KN415 34.662 KN440 13.552 
KN358 29.143 KN384 14.239 KN416 25.477 KN441 14.652 
KN359 46.007 KN385 17.528 KN417 14.652 KN442 10.38 
KN360 26.7155 KN386 10.889 KN418 21.307 KN443 13.727 
KN361 13.5285 KN387 10.955 KN419 15.924 KN445 15.973 
KN362 20.0665 KN388 12.976 KN421 15.973 KN446 32.311 
KN363 12.0495 KN391 10.299 KN422 22.453 KN447 13.694 
KN365 25.844 KN394 24.585 KN423 25.745 KN448 12.11 
KN366 25.1945 KN395 11.531 KN424 22.321 KN449 14.741 
KN367 39.264 KN396 18.112 KN425 12.557 KN450 13.516 
KN368 13.5295 KN397 15.973 KN426 16.76 KN451 15.706 
KN369 12.051 KN398 10.405 KN427 31.954 KN452 13.611 
KN370 26.132 KN399 12.599 KN428 11.925 
  
 
 
  
73 
 
Appendix D - Pearson's correlation coefficient results between END for 
MYLK1 copy number and quantitative variables. IKR; isokinetic right, IKL; 
isokinetic left 
 
Trait 
MYLK1 Copy number END 
associations 
p-value Coefficient R
2
 (%) 
Number of pull-ups 0.626 0.055 0.30 
CMJ height (cm) 0.399 -0.095 0.90 
Static jump height (cm) 0.783 0.031 0.10 
Sprint 0-10 (s/kgFFM) 0.979 0.003 0.00 
Sprint 10-20 (s/kgFFM) 0.789 -0.031 0.09 
Sprint 20-30 (s/kgFFM) 0.676 -0.048 0.23 
Sprint Total (s/kgFFM) 0.846 -0.022 0.05 
IKR knee flexion torque (30 °/s) 0.361 0.108 1.16 
IKL knee flexion torque (30 °/s) 0.686 0.048 0.23 
IKR knee flexion torque (90 °/s) 0.380 0.104 1.07 
IKL knee flexion torque (90 °/s) 0.708 0.044 0.20 
IKR knee flexion torque (180 °/s) 0.596 0.063 0.39 
IKL knee flexion torque (180 °/s) 0.727 0.041 0.17 
IKR elbow extension torque (30 °/s) 0.737 0.040 0.16 
IKL elbow extension torque (30 °/s) 0.451 0.089 0.79 
IKR elbow extension torque (90 °/s) 0.537 -0.073 0.53 
IKL elbow extension torque (90 °/s) 0.509 0.078 0.61 
IKR elbow extension torque (180 °/s) 0.731 -0.041 0.16 
IKL  elbow extension torque (180 °/s) 0.766 0.035 0.12 
IKR elbow flexion torque (30 °/s) 0.704 0.045 0.20 
IKL  elbow flexion torque (30 °/s) 0.805 -0.029 0.09 
IKR elbow flexion torque (90 °/s) 0.542 -0.072 0.52 
IKL  elbow flexion torque (90 °/s) 0.366 -0.107 1.14 
IKR elbow flexion torque (180 °/s) 0.701 -0.045 0.21 
IKL  elbow flexion torque (180 °/s) 0.562 -0.068 0.47 
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Appendix E – Increases in performance per copy number in the whole cohort 
for quantitative phenotypes which displayed significant correlations after BH 
corrections. IKR: isokinetic right, IKL; isokinetic left. 
 
Trait Copy number test p-value 
Percentage Change 
(%) 
Static jump height 
(cm) 
2 vs 1 0.248 17.98 
3 vs 2 0.036 11.81 
3 vs 1 0.041 31.92 
Sprint 0-10 
(s/kgFFM) 
2 vs 1 0.315 -2.41 
3 vs 2 0.015 -10.04 
3 vs 1 0.113 -12.21 
Sprint 10-20 
(s/kgFFM) 
2 vs 1 0.722 -1.16 
3 vs 2 0.008 -11.54 
3 vs 1 0.139 -12.52 
Sprint Total 
(s/kgFFM) 
2 vs 1 0.661 -1.11 
3 vs 2 0.010 -10.97 
3 vs 1 0.123 -11.96 
IKL knee extension 
torque (90 °/s) 
2 vs 1 0.447 13.97 
3 vs 2 0.016 14.97 
3 vs 1 0.148 31.04 
IKR elbow extension 
torque (30 °/s) 
2 vs 1 0.994 0.18 
3 vs 2 0.002 28.86 
3 vs 1 0.220 29.10 
IKL elbow extension 
torque(30 °/s) 
2 vs 1 0.676 7.43 
3 vs 2 0.006 26.42 
3 vs 1 0.110 35.81 
IKR elbow extension 
torque(180 °/s) 
2 vs 1 0.879 -2.30 
3 vs 2 0.001 37.62 
3 vs 1 0.181 34.45 
IKR elbow flexion 
torque (30 °/s) 
2 vs 1 0.949 0.90 
3 vs 2 0.005 21.68 
3 vs 1 0.195 22.78 
IKL elbow flexion 
torque (180 °/s) 
2 vs 1 0.810 -1.41 
3 vs 2 0.002 27.47 
3 vs 1 0.205 25.67 
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Appendix F – Increases in performance per copy number in STP for 
quantitative phenotypes which displayed significant correlations after BH 
corrections. 
 
Trait Test p-value 
Percentage 
Change (%) 
Static jump height (cm) 
2 vs 1 0.012 35.49 
3 vs 2 0.233 7.25 
3 vs 1 0.064 45.32 
IKRA, extension 180d/sec., N*mLOG10 
2 vs 1 0.350 14.54 
3 vs 2 0.004 28.33 
3 vs 1 0.106 46.99 
IKLA,  flexion 180d/sec., N*mLOG10 
2 vs 1 0.354 14.45 
3 vs 2 0.010 25.07 
3 vs 1 0.069 43.14 
 
 
